WO2021211098A1 - Prevention and treatment of viral infection-induced organ failure - Google Patents
Prevention and treatment of viral infection-induced organ failure Download PDFInfo
- Publication number
- WO2021211098A1 WO2021211098A1 PCT/US2020/028112 US2020028112W WO2021211098A1 WO 2021211098 A1 WO2021211098 A1 WO 2021211098A1 US 2020028112 W US2020028112 W US 2020028112W WO 2021211098 A1 WO2021211098 A1 WO 2021211098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organ failure
- virus
- subject
- viral infection
- organ
- Prior art date
Links
- 206010053159 Organ failure Diseases 0.000 title claims abstract description 73
- 230000009385 viral infection Effects 0.000 title claims abstract description 60
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 title description 15
- 230000002265 prevention Effects 0.000 title description 2
- 102100029655 Tripartite motif-containing protein 72 Human genes 0.000 claims abstract description 205
- 101150088302 trim72 gene Proteins 0.000 claims abstract description 199
- 238000000034 method Methods 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 101000795210 Homo sapiens Tripartite motif-containing protein 72 Proteins 0.000 claims abstract description 11
- 102000052430 human TRIM72 Human genes 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 33
- 206010016654 Fibrosis Diseases 0.000 claims description 24
- 230000004761 fibrosis Effects 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 23
- 210000004072 lung Anatomy 0.000 claims description 21
- 239000002552 dosage form Substances 0.000 claims description 20
- 239000003443 antiviral agent Substances 0.000 claims description 19
- 230000000116 mitigating effect Effects 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 241001493065 dsRNA viruses Species 0.000 claims 2
- 238000001727 in vivo Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 26
- 241000711408 Murine respirovirus Species 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 20
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 20
- 241000711573 Coronaviridae Species 0.000 description 19
- 241000712461 unidentified influenza virus Species 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 208000025721 COVID-19 Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- -1 certolizumab Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 229920003141 Eudragit® S 100 Polymers 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000034486 Multi-organ failure Diseases 0.000 description 5
- 208000010718 Multiple Organ Failure Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000004797 therapeutic response Effects 0.000 description 5
- 150000003751 zinc Chemical class 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000712892 Arenaviridae Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 206010050685 Cytokine storm Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000238681 Ixodes Species 0.000 description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000711504 Paramyxoviridae Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 241000150350 Peribunyaviridae Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000711931 Rhabdoviridae Species 0.000 description 3
- 241000710924 Togaviridae Species 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- PCGISRHGYLRXSR-UHFFFAOYSA-N 4-hydroxy-7-[(5-hydroxy-7-sulfonaphthalen-2-yl)carbamoylamino]naphthalene-2-sulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(NC(=O)NC=3C=C4C=C(C=C(C4=CC=3)O)S(O)(=O)=O)=CC=C21 PCGISRHGYLRXSR-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 241000256111 Aedes <genus> Species 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 241000256113 Culicidae Species 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 101710154794 Tripartite motif-containing protein 72 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229960000366 emtricitabine Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108010039636 3-isopropylmalate dehydrogenase Proteins 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000150347 Bunyavirales Species 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000776471 DPANN group Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000238703 Ixodes scapularis Species 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000003140 Kyasanur forest disease Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000022899 Pogosta disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000007009 Ross river fever Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000736032 Sabia <angiosperm> Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000012898 one-sample t-test Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005430 oxychloro group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960004599 sodium borate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 229940006486 zinc cation Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940046253 zinc orotate Drugs 0.000 description 1
- 229940032991 zinc picolinate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- YNMDOZLVAPMCBD-UHFFFAOYSA-L zinc;2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [Zn+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 YNMDOZLVAPMCBD-UHFFFAOYSA-L 0.000 description 1
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention concerns compositions for and methods of preventing, reversing, and/or treating viral infection-induced organ failure.
- a composition comprising (or expressing) a therapeutically effective amount of MG53 is administered to a subject suffering from a viral infection that induces organ failure, thereby preventing, reversing and/or treating organ failure.
- the invention also provides a method of decreasing the mortality rate in a population of subjects suffering from a viral infection that induces organ failure.
- Organ failure also referred to as multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF), total organ failure (TOF), multisystem organ failure (MSOF)
- MODS multiple organ dysfunction syndrome
- MOF multiple organ failure
- TOF total organ failure
- MSOF multisystem organ failure
- Viral infection, bacterial infection, or physical injury may cause organ failure. Numerous viruses are known to cause mortality by inducing organ failure in subjects.
- Such viruses include disseminated herpes simplex virus- 1, Ebolavirus, Marburgvirus, coronavirus (CoV), hemorrhagic viruses, filovirus, rabies virus, AIDS/HIV, smallpox virus, influenza virus (A through D), Hanta virus (Hantavirus pulmonary syndrome), Dengue fever virus, rotavirus, SARS-CoV, MERS-CoV, SARS-CoV-2 (COVID-19), Coronavirus 229E, Coronavirus NI63, Coronavirus Oc43, Yellow fever virus, Lassa fever virus, Japanese encephalitis virus, Spanish influenza virus, Hong Kong influenza, Influenza A & B, Parainfluenza 1-4, Adenovirus, Coxsackievirus, Metapneumovirus, Rhinovirus/enterovirus, Respiratory syncytial virus and others.
- viruses target particular organs such as the lung, heart, kidney, and/or liver.
- organs such as the lung, heart, kidney, and/or liver.
- influenza virus and SARS-CoV-2 infections the primary cause of death is pneumonia and severe acute respiratory distress because the viruses target the lungs; however, multiple organ failure is also observed.
- coronavirus disease 2019 (COVTD-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a devastating global health emergency.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- ARDS and vital organ including heart, liver, intestine, and kidney
- Acute respiratory infections also comprise a large threat for the soldiers and veterans due to exposure, close quarters, and environmental risks.
- a vaccine against coronaviruses has yet to be developed.
- SARS-CoV predominantly infects airway and alveolar epithelial cells, vascular endothelial cells, and macrophages.
- the early onset of rapid viral replication may cause massive epithelial and endothelial cell death and vascular leakage, triggering the event of exuberant “inflammatory cytokine storm”.
- SARS-CoV-2 and/or influenza infection may also cause injury and death of macrophages and lymphocytes, which compromise the innate and adaptive immune responses.
- Inflammatory cytokine storm- induced tissue injuries are a key contributing factor to respiratory dysfunction and multi-organ failure associated with virus infection.
- ARDS Major clinical manifestations of ARDS, including arterial hypoxemia and pulmonary edema, are direct consequences of the disrupted airway and alveolar barrier function. Therefore, effective ARDS treatment and multi-organ protection requires suppressing the virus-induced inflammatory cytokine storm, resolution of alveolar edema, and most critically the restoration of epithelial and endothelial barrier integrity.
- Fibrosis is known to be etiologically related to organ failure. Guo et al. (Exp. Cell Res. (2016), 362(2), 436-443) report that MG53 could induce atrial fibrosis. Chen et al. (J. Cell. Physiol. (2019), 234(10), 17749-17756) report that MG53 causes cardiac fibrosis. Liu et al. (Circ. (2015), 131(9), 795-804) report that cardiac-specific transgenic expression of MG53 induces diabetic cardiomyopathy in mice. Hu et al. (Biochim. Biophys.
- the present inventors seek to prevent, reverse or treat viral infection-induced organ failure by administration of MG53 or of an MG53 -expressing composition.
- the compositions and dosage forms herein can achieve said goal(s).
- One object of the invention is to provide a recombinant human MG53 (rhMG53) protein for preventing, reversing, and/or treating viral infection-induced organ failure. Another object of the invention is to administer said rhMG53 to a subject having a virus infection that induces organ failure. Another object of the invention is to reduce the mortality rate in a population of subjects infected with a virus that induces fatal organ failure. Yet another object of the invention is to mitigate virus infection-induced fibrosis of one or more organs of a subject infected with a virus that induces organ fibrosis. In order to achieve key objectives, the present invention provides the following technical solutions.
- An aspect of the invention provides a method of preventing viral infection-induced organ failure, the method comprising administering to a subject, infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure.
- the subject may or may not have contracted said viral infection before administration of MG53.
- Another aspect of the invention provides a method of preventing viral infection- induced organ failure, the method comprising administering to a subject, at risk of being infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure, said subject not yet having contracted said viral infection prior to administration of MG53.
- Another aspect of the invention provides a method of reversing viral infection- induced organ failure, the method comprising administering to a subject, exhibiting (indicated with) viral infection-induced organ failure, one or more doses of MG53, thereby reversing said organ failure. Said subject would have already contracted said viral infection and would already be exhibiting one or more signs/symptoms of failure of one or more organs.
- Another aspect of the invention provides a method of reducing the mortality rate in a population of subjects having a viral infection that causes mortality due to organ failure, the method comprising administering to subjects of said population one or more doses of MG53, thereby reducing the mortality rate in said population of subjects.
- Another aspect of the invention provides a method of mitigating (e.g. ameliorating, treating, curing) virus-infection induced organ fibrosis, which may or may not be fatal, the method comprising administering to a subject, infected with a virus that induces organ fibrosis, one or more doses of MG53, thereby mitigating fibrosis of one or more organs of said subject.
- said organ failure is short-term or acute organ failure, meaning organ failure that occurs over a period of hours, days, weeks or up to about three months.
- said organ failure is long-term or chronic organ failure, meaning organ failure that occurs over a period of about three months or more.
- MG53 can be administered acutely, chronically or a combination thereof. MG53 can be administered according to any dosing regimen that is clinically and/or therapeutically beneficial to a subject receiving it. It can be administered orally, by injection, intravenously, intratracheally, inhalation, nasal spray, aerosol delivery system, nebulizer, intraarterially, subcutaneously, intramuscularly, rectally, by infusion, directly to a target organ, and/or transdermally.
- MG53 can be included in any dosage form or kit suitable for administration to a subject in need thereof.
- Acceptable dosage forms include injectable, intratracheal , oral, peroral, rectal, spray, topical, transdermal, buccal, aerosol delivery system, and nebulizer.
- Such dosage forms exhibit one or more release profiles selected from the group consisting of immediate release, rapid release, extended release, sustained release, controlled release, enteric release, and a combination of any thereof.
- MG53 may be administered systemically or non-systemically.
- the methods of invention can further comprise administration of MG53 and one or more antiviral drug(s) to a subject infected with a virus that induces organ failure.
- Said antiviral drug(s) may be administered in combination with MG53 or separately from MG53.
- the administration of MG53 and said one or more antiviral drug(s) can be separate, simultaneous, overlapping or sequential.
- the vims that induces organ failure and/or causes mortality can be selected from the group consisting of positive-sense single-stranded RNA vims ((+)-ss-envRNAV), negative- sense single-stranded RNA vims ((-)-ss-envRNAV), double-stranded DNA vims (ds- DNAV), or positive-sense RNA via DNA vims.
- the viral infection is caused by any of the following vims families: Arenaviridae, Arterviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Retroviridae (in particular, Deltaretrovims genus), Coronaviridae, Togaviridae, Herpesviridae, Poxviridae or Hepadnaviridae.
- vims families Arenaviridae, Arterviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Retroviridae (in particular, Deltaretrovims genus), Coronaviridae, Togaviridae, Herpesviridae, Poxviridae or Hepadnaviridae.
- the (+)-ss-envRNAV is a vims selected from the group consisting of Coronaviridae family, Flaviviridae family, Togaviridae family, and Arterviridae family.
- the (+)-ss-envRNAV is a coronavims that is pathogenic to humans.
- the coronavims is selected from the group consisting of SARS-CoV, MERS-CoV, COVID-19 (SARS-CoV-2), CoV 229E, CoV NL63, CoV OC43, CoV HKU1, and CoV HKU20.
- the (+)-ss-envRNAV is a vims selected from the group consisting flavivims, Yellow Fever vims, Dengue Fever vims, Japanese Enchephalitis vims, West Nile vims, Zikavims, Tick-borne Encephalitis vims, Kyasanur Forest Disease vims, Alkhurma Disease vims, Omsk Hemorrhagic Fever vims, and Powassan vims.
- the (+)-ss-envRNAV is a Togaviridae family vims selected from the group consisting arborvims, eastern equine encephalomyelitis vims (EEEV), western equine encephalomyelitis vims (WEEV), Venezuelan equine encephalomyelitis vims (VEEV), Chikungunya vims (CHIKV), O’nyong’nvirus (ONNV), Pogosta disease vims, Sindbis vims, Ross River fever vims (RRV) and Semliki Forest vims.
- the invention includes embodiments wherein the viral infection is CoV that is pathogenic to humans, e.g. SARS-CoV, MERS-CoV, COVID-19 (SARS-CoV-2), CoV 229E, CoV NL63, CoV OC43, CoV HKU1, and CoV HKU20.
- CoV that is pathogenic to humans
- SARS-CoV MERS-CoV
- COVID-19 SARS-CoV-2
- CoV 229E CoV NL63
- CoV OC43 CoV HKU1
- CoV HKU20 CoV HKU
- the (-)-(ss)-envRNAV is a vims selected from the Arenaviridae family, Bunyaviridae family (Bunyavirales order), Filoviridae family, Orthomyxoviridae family, Paramyxoviridae family, or Rhabdoviridae family.
- Arenaviridae family vims is selected from the group consisting of Lassa vims, aseptic mengitis, Guanarito vims, Junin vims, Lujo vims, Machupo vims, Sabia vims and Whitewater Arroyo vims.
- Bunyaviridae family vims is selected from the group consisting of Hantavims, and Crimean-Congo hemorrhagic fever orthonairovims.
- Paramyxoviridae family vims is selected from the group consisting of Mumps vims, Nipah vims, Hendra vims, respiratory syncytial vims (RSV), human parainfluenza vims (HPIV), and NDV.
- Orthomyxoviridae family vims is selected from the group consisting of influenza vims (A through C), Isavims, Thogotovims, Quaranjavims, H1N1 vims, H2N2 vims, H3N2 vims, H1N2 vims, Spanish flu vims, Asian flu vims, Hong Kong Flu vims, and Russian flu vims.
- Rhabdoviridae family vims is selected from the group consisting of rabies vims, vesiculovims, Lyssavims, and Cytorhabdovims.
- the organ that undergoes vims infection-induced organ failure can be the respiratory system, heart, lung, kidney, gastrointestinal system and/or liver.
- the composition further comprises one or more zinc salts present in an amount sufficient to stabilize MG53 present in the composition.
- the molar ratio of Zn ions present to MG53 molecules present is at least 2:1, when considering the two zinc ion binding sites present on each MG53 molecule.
- the composition comprises a molar ratio of >2: 1 for the moles of Zn to moles of MG53.
- the method of the invention further comprises adjunct administration of with at least one antioxidant, whereby said at least one antioxidant is administered prior to, along with, or after administration of MG53.
- the method of the invention can further comprise the step of administering at least one antioxidant to a subject.
- the molar ratio ofMG53 to antioxidant can be in the range of 0.01:1 to 10:1.
- a subject is chronically administered MG53, at least one antioxidant, and at least one zinc salt.
- the invention also provides a composition comprising MG53, at least one antioxidant, and at least one zinc salt.
- the molar ratio of MG53 to antioxidant can be in the range of 0.01 : 1 to 10: 1.
- a composition of the invention can be administered one, two, three or more times per day. It can be administered daily, weekly, monthly, bimonthly, quarterly, semiannually, annually or even longer as needed. It can be administered every other day, five times per week, four times per week, three times per week, two times per week, once daily, twice daily, one to four times daily, continuously, or as frequently or infrequently as needed.
- the unit dose of each administration is independently selected upon each occurrence from the doses described in this specification or as determined to be therapeutically effective. All combinations of the dosing regimens described are contemplated to be within the scope of the invention.
- the composition may be administered one or more times over a treatment period of at least one week.
- the composition may be administered acutely or chronically.
- the chronic administration is at least one weekly, at least once daily, two or more times daily, two or more times per week, or as needed at a dose of about 0.01 mg of MG53/kg of bodyweight to about 10 mg of MG53 /kg of bodyweight.
- the invention also provides the methods of treatment herein employing an enteric release composition comprising MG53, at least one enteric release material, and one or more pharmaceutical excipients. Following oral or peroral administration, the enteric release composition can be used to deliver MG53 to the gastrointestinal tract of a subject.
- the invention also provides a method of preventing, reversing or treating viral infection induced organ failure comprising administering to a subject an effective amount of said enteric release composition.
- FIG. 1 depicts a chart of the relative expression of MG53 in THP1 cells. Quantification of reduction in MG53 protein expression following SeV infection (data representative of three independent experiments at the 24 h timepoint and two independent experiments at the 48 h timepoint; mean ⁇ SD; *** p ⁇ 0.001, **** p ⁇ 0.0001; One sample t-tests).
- FIG. 2. depicts a photograph of a gel comparing the effect of Sendai virus (SeV) and influenza virus H1N1 strain PR8 infection upon MG53 expression in THP1 cells.
- FIG. 3 depicts a chart of the percentage of SeV-GFP (green fluorescent protein labelled SeV) positive cells. Quantification of percentage of SeV-GFP positive cells (data representative of 4 independent experiments; mean ⁇ SD; unpaired t-test).
- FIG. 4B depicts a chart of the viral titer in lung and heart tissue of wild type (WT) and knockout (KO) mice five days after infection with influenza virus.
- FIG. 5 depicts a graph of percent body mass versus time (day) for WT C57BL/6J mice (8 week old Jackson laboratories) intranasally infected with 100 TCID50 Influenza A virus PR8 in 50 ul sterile saline, then intravenously treated with saline as control and rhMG53 (2mg/kg, in saline). See Example 5.
- Mice were monitored daily for (A) body mass and (B) survival. All untreated infected mice lost weight until death (see FIG. 6); whereas all treated infected mice lost weight during the first half of the 2-week study period but ultimately regained full body weight by the end of the 2-week study period.
- FIG. 6 depicts a graph of the survival rate of the mice of FIG. 5. All untreated infected mice died by day-8; whereas almost all treated infected mice survived beyond the 2- week endpoint of the study.
- FIG. 7 depicts a chart of the viral titer of TCID50 in the lung tissue of the mice of FIG. 5 at day 7 post infection. There was no substantial difference in viral titer between treated and untreated infected mice.
- FIG. 8 depicts photographs of lung tissue after Trichrome staining after the mice of FIG. 5 were euthanized and lung tissues were collected.
- the Trichrome staining showed the extent of fibrosis (stained blue lesions) in the lungs.
- rhMG53 treatment (right) reduced the formation of viral infection-induced fibrosis as compared to saline control (left).
- MG53 protein (also referred to as mitsugumin 53 or TRIM72) is known in the art. Unless specified otherwise, all embodiments of the invention comprising or employing “MG53” include all known forms of MG53. It also refers to recombinant human MG53 (rhMG53). As used herein and unless otherwise specified, the term MG53 (or MG53 protein) refers to the MG53 protein present as the native form, optimized form thereof, mutant thereof, derivative thereof or a combination of any two or more of said forms. Native MG53 contains 477 amino acids that are well conserved in different animal species.
- sequence listing information for native MG53, and variants or various forms thereof, is disclosed in US7981866 and US9139630, the entire disclosures of which, including sequence information therein, are hereby incorporated by reference.
- sequence listing information for a cDNA that encodes optimized native human MG53, or a fragment thereof, is disclosed in US9139630, the entire disclosure of which, including sequence information therein, is hereby incorporated by reference.
- mutant means a recombinant form of MG53 having an amino acid change (replacement) of one, two, three or more amino acids in the amino acid sequence of native MG53.
- Mutant forms of MG53 and methods of preparing the same are known: US2015/0361146, EP3118317, WO2015/131728, US9139630, the entire disclosures of which, including sequence information therein, are hereby incorporated by reference.
- endogenous MG53 refers to MG53 present in a subject prior to treatment with a composition or method according to the invention.
- exogenous MG53 is nonendogenous MG53.
- a subject at risk of viral infection is: a) a subject living in a geographical area within which mosquitos, in particular Aedes species ( Aedes egypti, Aedes albopictus ) mosquitos, live; b) a subject living with or near a person or people having viral infection; c) a subject having sexual relations with a person having a viral infection; d) a subject living in a geographical area within which ticks, in particular Ixodes species ⁇ Ixodes marx, Ixodes scapularis, or Ixodes cooke species) ticks, live; e) a subject living in a geographical area within which fruit bats live; f) subj ects living in a tropical region; g) subj ects living in Africa; h) subjects in contact with bodily fluids of other subjects having a viral infection; i) a child; or j) a subject with a weakened immune system
- subj ecf is taken to mean warm blooded creatures such as mammals, for example, cats, dogs, mice, guinea pigs, horses, bovine cows, sheep, and humans.
- the present inventors have unexpectedly discovered that virus infection-induced organ failure can be prevented, reversed or treated by administration of MG53 to a subject having a virus infection that causes organ failure.
- Example 1 An in vitro viral assay was developed (Example 1) to determine whether MG53 expression is altered in THP1 cells upon infection with SeV (Sendai virus). We observed that SeV infection reduced MG53 protein expression by more than 50% (FIG. 1). This suggests that MG53 levels in cells are decreased during certain viral infections.
- MG53 wild type (WT) and knockout (KO) mice were intranasally infected with influenza virus strain PR8 at a dose of 10 tissue culture infectious dose 50 (TCID50) (Example 4). This dose causes weight loss in WT mice, peaking around day 10, followed by a full recovery of body weight. Even though MG53 has no direct antiviral activity, we observed in MG53 KO mice a more severe decrease in weight following infection and a delayed recovery compared to WT mice (FIG. 4A). This suggests that MG53 provides defense against morbidity during respiratory infection with influenza virus.
- TCID50 tissue culture infectious dose 50
- mice were divided into two groups with each group receiving the same dose of influenza virus (100 TCID50 influenza A virus H1N1 strain PR8.
- the control group was not administered MG53, and the test group was administered exogenous MG53 (dose: 2mg/kg).
- the body weight of the mice was monitored (FIG. 5).
- FIG. 6 After 8 days, all of the untreated mice had died, and all of the treated mice survived (FIG. 6). By day-14, all of the treated mice had completely recovered. Bodyweight of those mice was also recorded (FIG. 5). The treated mice were then euthanized. Post-mortem examination of the lung and heart of control and test mice was conducted. It was determined that the untreated control mice died of organ failure.
- Lungs were collected from the euthanized mice and stored in 4% PFA for histological analysis. Lung tissue Trichrome staining (Example 13) showed the lungs derived from mice treated with rhMG53 (FIG. 8: right) have less viral infection-induced fibrosis as compared to untreated saline control mice (FIG. 8: left).
- the invention also provides a method of mitigating viral infection-induced organ fibrosis, which might or might not be fatal. Contrary to what is suggested in the art, administration of exogenous MG53 is useful for preventing, reversing or treating long-term organ failure, in particular for mitigating viral infection induced organ fibrosis.
- a subject having a viral infection that induces organ fibrosis is administered MG53 according to a dosing regimen as described herein.
- virus infection-induced fibrosis in the subject’s organ is reduced (reversed) or progression of fibrosis is slowed or delayed compared to what might be expected (based upon comparison to an average population of subjects having said viral infection) had the subject not been administered MG53.
- the invention thus provides a method of preventing, reversing or treating organ failure, in particularly short-term or acute organ failure, in a subject infected with a virus that causes said organ failure. It also provides a method reducing the mortality rate in a population of subjects infected with a virus that causes said organ failure. It also provides a method of mitigating or reducing viral infection-induced organ fibrosis in a subject infected with a virus that causes organ fibrosis.
- the present method invention comprises: administering to the subject in need thereof a therapeutically relevant dose of MG53 (MG53-containing composition or MG-53-expressing composition) and a therapeutically relevant dose of said one or more other antiviral agents, wherein the MG53 is administered according to a first dosing regimen and the one or more other antiviral agents is administered according to a second dosing regimen.
- the first and second dosing regimens are the same. In some embodiments, the first and second dosing regimens are different.
- Methods of the invention include separate administration or coadministration of the MG53 with at least one other known antiviral composition, meaning the MG53 can be administered before, during or after administration of a known antiviral composition.
- a composition for treating symptoms associated with the viral infection can also be administered to the subject to which MG53 is being administered.
- medications used to treat inflammation, vomiting, nausea, headache, fever, diarrhea, nausea, hives, conjunctivitis, malaise, muscle pain, joint pain, seizure, or paralysis can be administered with or separately from the antiviral composition of the invention.
- the one or more other antiviral agents can be administered at doses and according to dosing regimens that are clinician-recognized as being therapeutically effective or at doses that are clinician-recognized as being sub-therapeutically effective.
- the clinical benefit and/or therapeutic effect provided by administration of a combination of MG53 and one or more other antiviral agents can be additive or synergistic, such level of benefit or effect being determined by comparison of administration of the combination to administration of the individual MG53 and one or more other antiviral agents.
- the one or more other antiviral agents can be administered at doses and according to dosing regimens as suggested or described by the Food and Drug Administration, World Health Organization, European Medicines Agency (E.M.E.A.), Therapeutic Goods Administration (TGA, Australia), Pan American Health Organization (PAHO), Medicines and Medical Devices Safety Authority (Medsafe, New Zealand) or the various agencies of Health worldwide.
- Food and Drug Administration World Health Organization, European Medicines Agency (E.M.E.A.), Therapeutic Goods Administration (TGA, Australia), Pan American Health Organization (PAHO), Medicines and Medical Devices Safety Authority (Medsafe, New Zealand) or the various agencies of Health worldwide.
- antiviral agents that can be included in the method (and/or composition) of the invention for the treatment of viral infection-induced organ failure include antiretroviral agent, interferon alpha (IFN-a), zidovudine, lamivudine, cyclosporine A, CHOP with arsenic trioxide, sodium valproate, methotrexate, azathioprine, one or more symptom alleviating dmg(s), steroid sparing drug, corticosteroid, cyclophosphamide, immunosuppressant, anti-inflammatory agent, Janus kinase inhibitor, tofacitinib, calcineurin inhibitor, tacrolimus, mTOR inhibitor, sirolimus, everolimus, IMDH inhibitor, azathioprine, leflunomide, my cophenol ate, biologic, abatacept, adalimumab, anakinra, certolizumab, etanercept,
- IFN-a
- Antibodies to specific viruses may also be administered to a subject treated with the antiviral composition of the invention.
- Plasma obtained from the blood of survivors of a first viral infection can be administered to other subjects having the same type of viral infection, said other subjects also being administered the antiviral composition of the invention.
- the plasma from a survivor of COVID-19 infection may be administered to another subject having a COVID-19 infection, said other subject also being administered the MG53 composition of the invention.
- MG53 may be administered to a subject in many different forms.
- MG53 can be degraded by proteases in the GI tract or by the acidic conditions of the stomach
- MG53 may be administered a probiotic composition whereby a safe microbe is engineered to express MG53.
- the probiotic composition is then administered orally (perorally) to a subject such that the microbe expresses MG53 in the GI tract of a subject.
- Exemplary probiotic compositions are disclosed in international application No. PCT/US2019/060684 to Ma, the entire disclosure of which is hereby incorporated by reference.
- an enteric release (ER) composition comprising MG53 was developed.
- the ER composition comprises MG53, an enteric release pharmaceutical excipient, and a cyclodextrin.
- the ER composition comprises MG53, at least one enteric release polymer, and at least one cyclodextrin derivative.
- the enteric release polymer is a copolymer of methacrylic acid and methyl methacrylate.
- the enteric release polymer has a dissolution pH of > about 5, > about 5.5, > about 6, > about 6.5, or > about 7.
- the cyclodextrin derivative is water soluble. In particular embodiments, the cyclodextrin derivative is hydroxypropyl-beta-cyclodextrin.
- the amount of therapeutic compound (MG53) incorporated in each dosage form will be at least one or more unit doses and can be selected according to known principles of pharmacy.
- An effective amount of therapeutic compound is specifically contemplated.
- an effective amount it is understood that, with respect to, for example, pharmaceuticals, a pharmaceutically (therapeutically) effective amount is contemplated.
- a pharmaceutically effective amount is the amount or quantity of a drug or pharmaceutically active substance which is sufficient to elicit the required or desired therapeutic response, or in other words, the amount which is sufficient to elicit an appreciable biological response when administered to a patient.
- Suitable concentrations of MG53 in a liquid dosage form include at least 1 ng of MG53/ml, at least 5 ng of MG53/ml, at least 10 ng of MG53/ml, at least 25 ng of MG53/ml, at least 50 ng of MG53/ml, at least 75 ng of MG53/ml, at least 100 ng of MG53/ml, at least 250 ng of MG53/ml, at least 500 ng of MG53/ml, at least 750 ng of MG53/ml, at least 1 Dg of MG53/ml, at least 5 Dg of MG53/ml, at least 10 Dg of MG53/ml, at least 15 Dg of MG53/ml, atleast20 DgofMG53/ml, atleast25 DgofMG53/ml, atleast30 DgofMG53/ml, at least 50 Dg of MG53/ml, or
- a dosing regimen includes a therapeutically relevant dose (or effective dose) of MG53 administered according to a dosing schedule.
- a therapeutically relevant dose therefore, is a therapeutic dose at which a therapeutic response of the organ failure to treatment with a composition as described is observed and at which a subject can be administered said composition without an excessive amount of unwanted or deleterious side effects.
- a therapeutically relevant dose is non-lethal to a subject, even though it may cause some side effects in the patient. It is a dose at which the level of clinical benefit to a subject being administered said composition exceeds the level of deleterious side effects experienced by the subject due to administration of said composition or component(s) thereof.
- a therapeutically relevant dose will vary from subject to subject according to a variety of established pharmacologic, pharmacodynamic and pharmacokinetic principles.
- a therapeutically relevant dose can be administered according to any dosing regimen typically used in the treatment of viral infection.
- a therapeutically relevant dose can be administered once, twice, thrice or more daily. It can be administered every other day, every third day, every fourth day, every fifth day, semiweekly, weekly, biweekly, every three weeks, every four weeks, monthly, bimonthly, semimonthly, every three months, every four months, semiannually, annually, or according to a combination of any of the above to arrive at a suitable dosing schedule.
- a therapeutically relevant dose can be administered one or more times daily (up to 10 times daily for the highest dose) for one or more weeks.
- Suitable doses of MG53 that can be administered to a subject in one or more dosage forms include at least 1 ng of MG53, at least 5 ng of MG53, at least 10 ng of MG53, at least 25 ng of MG53, at least 50 ng of MG53, at least 75 ng of MG53, at least 100 ng of MG53, at least 250 ng of MG53, at least 500 ng of MG53, at least 750 ng of MG53, at least 1 Dg of MG53, at least 5 Dg of MG53, at least 10 Dg of MG53, at least 15 Dg of MG53, at least 20 ⁇ g of MG53, at least 25 Dg of MG53, at least 30 Dg of MG53, at least 50 Dg of MG53, or at least 100 Dg of MG53.
- Such doses can be on a total body weight basis or a per kg of body weight basis.
- the dose of exogenous MG53 can be as low as about 1 microg per kg of body weight up to about 1000 microg per kg of body weight.
- unit dosage form is used herein to mean a dosage form containing a quantity of the MG53, said quantity being such that one or more predetermined units may be provided as a single therapeutic administration.
- the dosage form is independently selected at each occurrence from the group consisting of liquid solution, suspension, tablet, pill, vial, powder, granule, bead, caplet, capsule, sachet or powder.
- compositions and dosage forms of the invention can further comprise one or more pharmaceutically acceptable excipients.
- Dosage forms can comprise one or more excipients independently selected at each occurrence from the group consisting of acidic agent, alkaline agent, buffer, tonicity modifier, osmotic agent, water soluble polymer, water-swellable polymer, thickening agent, complexing agent, chelating agent, penetration enhancer.
- Suitable excipients include U.S.F.D.A.
- inactive ingredients approved for use in parenteral or oral formulations such as those listed in the U.S.F.D.A.’s “Inactive Ingredients Database (available on the following website: https://www.fda.gov/Drugs/InformationOnDrugs/ucml l3978.htm: Oct. 2018), the entire disclosure of which is hereby incorporated by reference.
- an acidic agent is a compound or combination of compounds that comprises an acidic moiety.
- exemplary acidic agents include organic acid, inorganic acid, mineral acid and a combination thereof.
- exemplary acids include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfonic acid, sulfamic acid, phosphoric acid, or nitric acid or others known to those of ordinary skill; and the salts prepared from organic acids such as amino acids, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2- acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid,
- an alkaline agent is a compound or combination of compounds that comprises an alkaline moiety.
- exemplary alkaline agents include primary amine, secondary amine, tertiary amine, quaternary amine, hydroxide, alkoxide, and a combination thereof.
- exemplary alkaline agents include ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, diethanolamine, monobasic phosphate salt, dibasic phosphate salt, organic amine base, alkaline amino acids and trolamine, others known to those of ordinary skill in the art, or combinations thereof.
- excipients active ingredients as defined by the U.S.F.D.A.
- active ingredients include, by way of example and without limitation, water, benzalkonium chloride, glycerin, sodium hydroxide, hydrochloric acid, boric acid, hydroxyalkylphosphonate, sodium alginate, sodium borate, edetate disodium, propylene glycol, polysorbate 80, citrate, sodium chloride, polyvinylalcohol, povidone, copovidone, carboxymethylcellulose sodium, Dextrose, Dibasic Sodium Phosphate, Monobasic Sodium Phosphate, Potassium Chloride, Sodium Bicarbonate, Sodium Citrate, Calcium Chloride, Magnesium Chloride, stabilized oxychloro complex, Calcium Chloride Dihydrate, Erythritol, Levocamitine, Magnesium Chloride Hexahydrate, Sodium Borate Decahydrate, Sodium
- antioxidants can be included in a composition or dosage form of the invention.
- Exemplary antioxidants include SS-31, NAC, glutathione, selenium, vitamin A, vitamin C, vitamin E, co-enzyme Q10, resveratrol, other GRAS antioxidant, or a combination of two or more thereof.
- One or more zinc salts can be included in a composition or dosage form of the invention. Such zinc salt(s) may also be administered to a subj ect receiving exogenous MG53 or expressed MG53.
- Pharmaceutically acceptable zinc salts include Zinc gluconate, Zinc acetate, Zinc sulfate, Zinc picolinate, Zinc orotate, Zinc citrate, and other such salts comprising a zinc cation and organic or inorganic anion(s).
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the compound is modified by making an acid or base salt thereof.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and others known to those of ordinary skill.
- the pharmaceutically acceptable salts can be synthesized from the parent therapeutic compound which contains a basic or acidic moiety by conventional chemical methods. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a composition, dosage form or formulation of the invention can include one, two or more active ingredients in combination with MG53.
- the dose of each said active ingredient in said composition, dosage form or formulation of the invention will be a therapeutically effective dose including and above the MED and including and below the MTD.
- the combination treatment of MG53 with another active ingredient provides at least additive therapeutic efficacy. In some embodiments, said combination provides synergistic therapeutic efficacy. In some embodiments, MG53 reduces the occurrence of, reduces the level of, or eliminates adverse events caused by the other active ingredient.
- the terms “about” or “approximately” are taken to mean a variation or standard deviation of ⁇ 10%, ⁇ 5%, or ⁇ 1% of a specified value. For example, about 20 mg is taken to mean 20 mg ⁇ 10%, which is equivalent to 18-22 mg.
- prodrug is taken to mean a compound that, after administration, is converted within a subject’s body, e.g. by metabolism, hydrolysis, or biodegradation, into a pharmacologically active drug.
- the prodrug may be pharmacologically active or inactive.
- a prodrug of MG53 native or mutant
- MG53 native or mutant
- precursor may also be used instead of the term “prodrug”.
- the term “derivative” is taken to mean: a) a chemical substance that is related structurally to a first chemical substance and theoretically derivable from it; b) a compound that is formed from a similar first compound or a compound that can be imagined to arise from another first compound, if one atom of the first compound is replaced with another atom or group of atoms; c) a compound derived or obtained from a parent compound and containing essential elements of the parent compound; or d) a chemical compound that may be produced from first compound of similar structure in one or more steps.
- a derivative may include a deuterated form, oxidized form, dehydrated, unsaturated, polymer conjugated or glycosilated form thereof or may include an ester, amide, lactone, homolog, ether, thioether, cyano, amino, alkylamino, sulfhydryl, heterocyclic, heterocyclic ring-fused, polymerized, pegylated, benzylidenyl, triazolyl, piperazinyl or deuterated form thereof.
- ranges are specified for the amount of each ingredient. Ranges including “0” as the lowest value indicate an optional ingredient. The lower limit “>0” indicates the respective material is present.
- compositions with quantities of ingredients falling within the compositional ranges specified herein were made.
- Compositions of the invention comprising quantities of ingredients falling within the compositional ranges specified herein operate as intended and as claimed.
- MG53 was kindly provided by TRIM-edicine, Inc. (1275 Kinnear RD, Columbus OH 43212-1155, U.S.A.). We thank Dr. Wayne Chen for providing the doxycycline inducible RyR2 expressing HEK293 cells, Drs. Juan Moliva and Jordi Torrelles for providing the primary human blood monocyte-derived macrophage protein lysates, and Dr. Anthony Garcin for providing SeV-GFP. EXAMPLE 1
- Sendai virus (SeV) expressing GFP, SeV strain Cantell, PR8 were propagated in embryonated chicken eggs and titered on LLCMK2 cells for SeV and MDCK cells for influenza virus.
- SeV-GFP and SeV infections were allowed to proceed for 24 or 48 hours using multiplicity of infections (MOIs) of 2 and 5 respectively.
- MOIs multiplicity of infections
- 24 hrs post SeV-GFP infection THP1 cells were washed in PBS and fixed using 4% paraformaldehyde. Cells were washed, resuspended in PBS, and analyzed with a FACSCanto II flow cytometer (BD Biosciences) to determine the percentage of GFP positive cells. Data was analyzed using FlowJo software.
- SeV and H1N1 influenza [0112] Sendai virus (SeV) expressing GFP, SeV strain Cantell, and influenza virus strain PR8 were propagated in embryonated chicken eggs and titered on LLCMK2 cells for SeV and MDCK cells for influenza virus. SeV-GFP and SeV infections were allowed to proceed for 24 or 48 hours using multiplicity of infections (MOIs) of 2 and 5 respectively. 24 hrs post SeV-GFP infection, THP1 cells were washed in PBS and fixed using 4% paraformaldehyde. Cells were washed, resuspended in PBS, and analyzed with a FACSCanto II flow cytometer (BD Biosciences) to determine the percentage of GFP positive cells. Data was analyzed using FlowJo software.
- Control shRNA SEQ ID 1: 5’-GACTGACATGTCAAGCTGTAC-3’
- MG53 shRNA SEQ ID 2: 5'- GAAGAGTGTGGCTGTGCTGGAGCATCAGC-3 ’
- HEK293-FT cells were transfected with packaging, envelope, and target plasmids. Media was changed 18 hours after transfection, followed by collection of virus-containing media 48 hours later. Virus-containing media was centrifuged at 1200 x g for 5 min and filtered with 0.45pm filters. THP1 cells were then incubated with viral media. After 24 hrs, media was replaced, and cells were allowed 48 hrs to recover.
- MG53 knockout mice were generated in the 129Sl/SvlmJ strain of mice. All mice were housed and handled following IACUC approved protocols.
- Murine intranasal influenza virus infections were carried out in 12-week-old male MG53 wild type and knockout mice. Animals were anesthetized using isoflurane and were intranasally infected with influenza virus strain A/PR/8/34 (H1N1) (PR8) at a dose of 10 tissue culture infectious dose 50 (TCID50) in 50 pL clinical grade saline. Mice were monitored daily and weights were recorded. Animals were euthanized at either day 5 post infection or at the experimental endpoint when they recovered to normal body weight. After animals were sacrificed, lungs and hearts were collected for viral titers, cytokine measurements, and histology.
- THP1 cells were purchased from ATCC and cultured in RPMI-1640 media supplemented with L-Glutamine and sodium pyruvate (Sigma R8758) in addition to 10% fetal bovine serum and 1% penicillin / streptomycin in a 5% C02 incubator. THP1 cells were differentiated using 100 ng/mL PMA (Sigma PI 585) for 48 hrs.
- HEK293 and HEK293FT cells were obtained from ATCC and cultured using Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a 5% C02 incubator.
- HEK293-RyR2 cells were provided by Dr.
- Membranes were blocked in 5% milk in TBS-T and probed with antibodies against MG53 (custom-made rabbit monoclonal antibody), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology (CST) catalog #2118), p65 (CST 8242), phospho-p65 (CST 3033), or RyR (Invitrogen MA3925).
- MG53 custom-made rabbit monoclonal antibody
- GPDH glyceraldehyde 3-phosphate dehydrogenase
- CST 8242 Cell Signaling Technology (CST) catalog #2118
- p65 CST 8242
- phospho-p65 CST 3033
- RyR Invitrogen MA3925
- rhMG53 is provided by TRIM-edicine, Inc. (Columbus, OH).
- EUDRAGIT S-100 Poly(methacylic acid-co-methyl methacrylate) 1:2
- EVONIK https://healthcare.evOnik.com/product/health-care/en/. The following procedure is used to prepare beads.
- the powder can be included in a capsule, caplet, tablet or other oral dosage form.
- the enteric release formulation comprises MG53, hydroxypropyl-beta-cyclodextrin (HP-b-CD), and methacrylic acid / methyl methacrylate anionic copolymer (EUDRAGIT S 100; dissolution in water at pH above 7.0). The following procedure was used.
- a known amount of powdered samples of MG53 containing enteric release composition was dispersed in pH 2 (0.01N HC1) solution for 2 hrs, followed by addition of NasPCri solution (9.7 g in 112.8 mL H2O; to pH 6.5), then followed by addition of same NasPCri solution to pH 7.5.
- the release experiments were performed in an orbital shaker at 37 °C and 150 rpm.
- MG53/CD/EETDRAGIT mixture Spraying drying of MG53/CD/EETDRAGIT mixture
- the MG53/CD/EEIDRAGIT mixture was produced by spray-drying using the laboratory scale ProCept 4M8-TriX spray-dryer (Zelzate, Belgium).
- Drug-polymer solutions were prepared in the binary solvent mixture of interest DCM/EtOH 2:1 (v/v) at 50 mg/mL.
- the feed solution flow rate was adjusted at 5 g/min.
- An atomizing air pressure of 0.65 bars was applied to a 1.2 mm bifluid nozzle to create a spray.
- the drying gas airflow was set at 0.35 m3/min and maintained at 65 °C.
- the lateral cooling air was kept constant at 100 L/min and dried particles were separated from the exhaust air within the medium cyclone (height/diameter of 242 mm/60 mm). After processing, the spray-dried material was stored in a vacuum oven for 48 h before analysis to eliminate the last traces of residual solvent.
- IP radio-immunoprecipitation
- 20 pL of magnetic protein G beads were washed in PBS three times and conjugated to 2 pg (per IP sample) of antibody (MG53, RyR, Mouse and Rabbit IgG) for 2 hours at room temperature while rocking.
- Bead- antibody conjugates were then washed 2 times with PBS and once with lysis buffer.
- 1 mg of protein lysate was added to beads and then samples were incubated at 4°C overnight while rocking. The following day, samples were washed 3 times in PBS and protein was eluted with 4% SDS and 2x Laemlli sample buffer. IP samples were then analyzed following the western blotting protocol stated earlier.
- a subject presenting with COVID-19 virus infection is prescribed MG53 composition, and therapeutically relevant doses are administered to the subject according to a prescribed dosing regimen for a period of time.
- the subject s level of therapeutic response (in terms of performance of one or more organs) is determined periodically. If the level of therapeutic response is too low at one dose, then the dose is escalated according to a predetermined dose escalation schedule until the desired level of therapeutic response in the subject is achieved. Treatment of the subject with MG53 is continued as needed and the dose or dosing regimen can be adjusted as needed until the patient reaches the desired clinical endpoint.
- Method A above, is followed except that the subject is prescribed and administered one or more other antiviral agents for the treatment of COVID-19 virus infection or symptoms thereof. Then one or more other antiviral agents can be administered before, after or with the MG53. Dose escalation (or de-escalation) of the one or more other antiviral agents can also be done.
- All values disclosed herein may have standard technical measure error (standard deviation) of ⁇ 10%.
- the term “about” or “approximately” is intended to mean ⁇ 10%, ⁇ 5%, ⁇ 2.5% or ⁇ 1% relative to a specified value, i.e. “about” 20% means 20 ⁇ 2%, 20 ⁇ 1%, 20 ⁇ 0.5% or 20 ⁇ 0.25%.
- the term “majority” or “major portion” is intended to mean more than half, when used in the context of two portions, or more than one-third, when used in the context of three portions.
- the term “minority” or “minor portion” is intended to mean less than half, when used in the context of two portions, or less than one-third, when used in the context of three portions. It should be noted that, unless otherwise specified, values herein concerning pharmacokinetic or dissolution parameters are typically representative of the mean or median values obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.
Description
PREVENTION AND TREATMENT OF VIRAL INFECTION-INDUCED ORGAN FAILURE
INCORPORATION BY REFERENCE
[001] In compliance with 37 CFR 1.52(e)(5), the instant application contains Sequence Listings which have been submitted in electronic format via EFS and which are hereby incorporated by reference. The sequence information contained in electronic file named TRIM43PCT_SEQ_ST25.txt, size 1 KB, created on April 14, 2020, using Patent-in 3.5.1, and Checker 4.4.6 is hereby incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[002] The U.S. Government has certain rights in this invention pursuant to the following grants. This work was supported by grants from the National Institutes of Health (NIH) to Dr. Jianjie Ma (grants No. DK106394, No. AR061385, No. AR070752, and No. HL138570), Department of Defense grant to Dr. Jianj ie Ma (DoD PR170989), and NIH grants to Dr. Jacob S. Yount (grants No. AI130110 and No. AH 42256). This work was also supported by a NIH T32 fellowship to Adam D. Kenney (funded by grant No. GM068412).
FIELD OF THE INVENTION
[003] The present invention concerns compositions for and methods of preventing, reversing, and/or treating viral infection-induced organ failure. A composition comprising (or expressing) a therapeutically effective amount of MG53 is administered to a subject suffering from a viral infection that induces organ failure, thereby preventing, reversing and/or treating organ failure. The invention also provides a method of decreasing the mortality rate in a population of subjects suffering from a viral infection that induces organ failure.
BACKGROUND OF THE INVENTION
[004] The etiology of Organ failure (OF; also referred to as multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF), total organ failure (TOF), multisystem organ failure (MSOF)) has not been fully characterized; however, uncontrolled inflammatory response, uncontrolled immune response, or fibrosis have been suggested as being directly or indirectly causative. Many biomechanistic pathways exist for organ failure, and no broad- spectrum curative or preventative compound (agent, active ingredient) has been found.
[005] Viral infection, bacterial infection, or physical injury may cause organ failure. Numerous viruses are known to cause mortality by inducing organ failure in subjects. Such viruses include disseminated herpes simplex virus- 1, Ebolavirus, Marburgvirus, coronavirus (CoV), hemorrhagic viruses, filovirus, rabies virus, AIDS/HIV, smallpox virus, influenza virus (A through D), Hanta virus (Hantavirus pulmonary syndrome), Dengue fever virus, rotavirus, SARS-CoV, MERS-CoV, SARS-CoV-2 (COVID-19), Coronavirus 229E, Coronavirus NI63, Coronavirus Oc43, Yellow fever virus, Lassa fever virus, Japanese encephalitis virus, Spanish influenza virus, Hong Kong influenza, Influenza A & B, Parainfluenza 1-4, Adenovirus, Coxsackievirus, Metapneumovirus, Rhinovirus/enterovirus, Respiratory syncytial virus and others. Some of these viruses target particular organs such as the lung, heart, kidney, and/or liver. For example, in influenza virus and SARS-CoV-2 infections, the primary cause of death is pneumonia and severe acute respiratory distress because the viruses target the lungs; however, multiple organ failure is also observed.
[006] The coronavirus disease 2019 (COVTD-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a devastating global health emergency. In addition to COVTD-19, the world is continually facing the challenge of seasonal and emergent influenza viruses, and other aggressive viral infections in epidemic proportions on a yearly basis. Irrespective of the origin of viral infection, ARDS and vital organ (including heart, liver, intestine, and kidney) failures are the main cause of morbidity and mortality associated with viral infections. Acute respiratory infections also comprise a large threat for the soldiers and veterans due to exposure, close quarters, and environmental risks. Despite extensive basic and translational research into influenza and coronavirus, a vaccine against coronaviruses has yet to be developed. Moreover, there is not a universal influenza vaccine effective against all influenza virus subtypes due to its high propensity to mutate, requiring seasonal influenza vaccines to be updated annually based on a projection of what strain might be prevalent. The lack of preventive vaccines against these viruses makes emerging influenza and coronaviruses a serious global threat, and calls for alternative therapy to treat virus- induced ARDS and multi-organ failures.
[007] Many studies have shown that SARS-CoV predominantly infects airway and alveolar epithelial cells, vascular endothelial cells, and macrophages. The early onset of rapid viral replication may cause massive epithelial and endothelial cell death and vascular leakage, triggering the event of exuberant “inflammatory cytokine storm”. In addition, SARS-CoV-2
and/or influenza infection may also cause injury and death of macrophages and lymphocytes, which compromise the innate and adaptive immune responses. Inflammatory cytokine storm- induced tissue injuries are a key contributing factor to respiratory dysfunction and multi-organ failure associated with virus infection. Major clinical manifestations of ARDS, including arterial hypoxemia and pulmonary edema, are direct consequences of the disrupted airway and alveolar barrier function. Therefore, effective ARDS treatment and multi-organ protection requires suppressing the virus-induced inflammatory cytokine storm, resolution of alveolar edema, and most critically the restoration of epithelial and endothelial barrier integrity.
[008] Methods of preparing, isolating, and/or using MG53 (mitsugumin 53; TRIM72) are known: US7981866, W02008/054561, W02008/060776, W02009/073808,
W02010/141810, WO2010/009312, US2011/0202033, US2011/0287004, US2011/0287015, US2013/0123340, WO2011/142744, WO2012/061793, US 8420338, US8603993, US8603992, US9139630, US9458465, US9494602, US9505821, US2014/0024594, WO2012/134478, WO2012/135868, US2015/0110778, W02013/036610, US2012/0213737, and WO2016/109638.
[009] US7981866 to Ma suggests that MG53 may have direct antiviral properties; however, the instant inventors have determined, as discussed herein, that MG53 does not have a direct antiviral property (at least in the virus tested herein), because it does not inhibit viral replication in cells infected with influenza virus.
[010] Fibrosis is known to be etiologically related to organ failure. Guo et al. (Exp. Cell Res. (2018), 362(2), 436-443) report that MG53 could induce atrial fibrosis. Chen et al. (J. Cell. Physiol. (2019), 234(10), 17749-17756) report that MG53 causes cardiac fibrosis. Liu et al. (Circ. (2015), 131(9), 795-804) report that cardiac-specific transgenic expression of MG53 induces diabetic cardiomyopathy in mice. Hu et al. (Biochim. Biophys. Acta (2018), 1864(5), part B, 1984-1990) report that sustained upregulation of MG53 disturbs metabolic processes and contributes to the development of muscle metabolic disorders. US8383602 to Kao states that “TRIM72 overexpression inhibits myogenesis” and “the inhibition of TRIM72 acts exclusively on skeletal muscle and heart muscle but does not affect IGF-I signaling pathway in other tissues”.
[Oil] Based upon the above art, the artisan would not expect MG53 to be useful toward preventing, reversing or treating acute or chronic organ failure, and it would be very
unexpected to find that MG53 could be used to prevent, reverse or treat viral infection-induced organ failure, be it acute (short-term) or chronic (long-term).
[012] It would be an advancement in the art to provide a method of and composition for preventing, reversing, and/or treating organ failure.
SUMMARY OF THE INVENTION
[013] The present inventors seek to prevent, reverse or treat viral infection-induced organ failure by administration of MG53 or of an MG53 -expressing composition. The compositions and dosage forms herein can achieve said goal(s).
[014] One object of the invention is to provide a recombinant human MG53 (rhMG53) protein for preventing, reversing, and/or treating viral infection-induced organ failure. Another object of the invention is to administer said rhMG53 to a subject having a virus infection that induces organ failure. Another object of the invention is to reduce the mortality rate in a population of subjects infected with a virus that induces fatal organ failure. Yet another object of the invention is to mitigate virus infection-induced fibrosis of one or more organs of a subject infected with a virus that induces organ fibrosis. In order to achieve key objectives, the present invention provides the following technical solutions.
[015] An aspect of the invention provides a method of preventing viral infection-induced organ failure, the method comprising administering to a subject, infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure. The subject may or may not have contracted said viral infection before administration of MG53. [016] Another aspect of the invention provides a method of preventing viral infection- induced organ failure, the method comprising administering to a subject, at risk of being infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure, said subject not yet having contracted said viral infection prior to administration of MG53.
[017] Another aspect of the invention provides a method of reversing viral infection- induced organ failure, the method comprising administering to a subject, exhibiting (indicated with) viral infection-induced organ failure, one or more doses of MG53, thereby reversing said organ failure. Said subject would have already contracted said viral infection and would already be exhibiting one or more signs/symptoms of failure of one or more organs.
[018] Another aspect of the invention provides a method of reducing the mortality rate in a population of subjects having a viral infection that causes mortality due to organ failure, the method comprising administering to subjects of said population one or more doses of MG53, thereby reducing the mortality rate in said population of subjects.
[019] Another aspect of the invention provides a method of mitigating (e.g. ameliorating, treating, curing) virus-infection induced organ fibrosis, which may or may not be fatal, the method comprising administering to a subject, infected with a virus that induces organ fibrosis, one or more doses of MG53, thereby mitigating fibrosis of one or more organs of said subject. [020] In some embodiments, said organ failure is short-term or acute organ failure, meaning organ failure that occurs over a period of hours, days, weeks or up to about three months.
[021] In some embodiments, said organ failure is long-term or chronic organ failure, meaning organ failure that occurs over a period of about three months or more.
[022] MG53 can be administered acutely, chronically or a combination thereof. MG53 can be administered according to any dosing regimen that is clinically and/or therapeutically beneficial to a subject receiving it. It can be administered orally, by injection, intravenously, intratracheally, inhalation, nasal spray, aerosol delivery system, nebulizer, intraarterially, subcutaneously, intramuscularly, rectally, by infusion, directly to a target organ, and/or transdermally.
[023] MG53 can be included in any dosage form or kit suitable for administration to a subject in need thereof. Acceptable dosage forms include injectable, intratracheal , oral, peroral, rectal, spray, topical, transdermal, buccal, aerosol delivery system, and nebulizer. Such dosage forms exhibit one or more release profiles selected from the group consisting of immediate release, rapid release, extended release, sustained release, controlled release, enteric release, and a combination of any thereof. MG53 may be administered systemically or non-systemically.
[024] The methods of invention can further comprise administration of MG53 and one or more antiviral drug(s) to a subject infected with a virus that induces organ failure. Said antiviral drug(s) may be administered in combination with MG53 or separately from MG53. The administration of MG53 and said one or more antiviral drug(s) can be separate, simultaneous, overlapping or sequential.
[025] The vims that induces organ failure and/or causes mortality can be selected from the group consisting of positive-sense single-stranded RNA vims ((+)-ss-envRNAV), negative- sense single-stranded RNA vims ((-)-ss-envRNAV), double-stranded DNA vims (ds- DNAV), or positive-sense RNA via DNA vims. In some embodiments, the viral infection is caused by any of the following vims families: Arenaviridae, Arterviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Retroviridae (in particular, Deltaretrovims genus), Coronaviridae, Togaviridae, Herpesviridae, Poxviridae or Hepadnaviridae.
[026] In some embodiments, the (+)-ss-envRNAV is a vims selected from the group consisting of Coronaviridae family, Flaviviridae family, Togaviridae family, and Arterviridae family. In some embodiments, the (+)-ss-envRNAV is a coronavims that is pathogenic to humans. In some embodiments, the coronavims is selected from the group consisting of SARS-CoV, MERS-CoV, COVID-19 (SARS-CoV-2), CoV 229E, CoV NL63, CoV OC43, CoV HKU1, and CoV HKU20.
[027] In some embodiments, the (+)-ss-envRNAV is a vims selected from the group consisting flavivims, Yellow Fever vims, Dengue Fever vims, Japanese Enchephalitis vims, West Nile vims, Zikavims, Tick-borne Encephalitis vims, Kyasanur Forest Disease vims, Alkhurma Disease vims, Omsk Hemorrhagic Fever vims, and Powassan vims.
[028] In some embodiments, the (+)-ss-envRNAV is a Togaviridae family vims selected from the group consisting arborvims, eastern equine encephalomyelitis vims (EEEV), western equine encephalomyelitis vims (WEEV), Venezuelan equine encephalomyelitis vims (VEEV), Chikungunya vims (CHIKV), O’nyong’nvirus (ONNV), Pogosta disease vims, Sindbis vims, Ross River fever vims (RRV) and Semliki Forest vims.
[029] The invention includes embodiments wherein the viral infection is CoV that is pathogenic to humans, e.g. SARS-CoV, MERS-CoV, COVID-19 (SARS-CoV-2), CoV 229E, CoV NL63, CoV OC43, CoV HKU1, and CoV HKU20.
[030] In some embodiments, the (-)-(ss)-envRNAV is a vims selected from the Arenaviridae family, Bunyaviridae family (Bunyavirales order), Filoviridae family, Orthomyxoviridae family, Paramyxoviridae family, or Rhabdoviridae family.
[031] In some embodiments, Arenaviridae family vims is selected from the group consisting of Lassa vims, aseptic mengitis, Guanarito vims, Junin vims, Lujo vims, Machupo vims, Sabia vims and Whitewater Arroyo vims.
[032] In some embodiments, Bunyaviridae family vims is selected from the group consisting of Hantavims, and Crimean-Congo hemorrhagic fever orthonairovims.
[033] In some embodiments, Paramyxoviridae family vims is selected from the group consisting of Mumps vims, Nipah vims, Hendra vims, respiratory syncytial vims (RSV), human parainfluenza vims (HPIV), and NDV.
[034] In some embodiments, Orthomyxoviridae family vims is selected from the group consisting of influenza vims (A through C), Isavims, Thogotovims, Quaranjavims, H1N1 vims, H2N2 vims, H3N2 vims, H1N2 vims, Spanish flu vims, Asian flu vims, Hong Kong Flu vims, and Russian flu vims.
[035] In some embodiments, Rhabdoviridae family vims is selected from the group consisting of rabies vims, vesiculovims, Lyssavims, and Cytorhabdovims.
[036] The organ that undergoes vims infection-induced organ failure can be the respiratory system, heart, lung, kidney, gastrointestinal system and/or liver.
[037] In some embodiments, the composition further comprises one or more zinc salts present in an amount sufficient to stabilize MG53 present in the composition. In a composition of the invention, the molar ratio of Zn ions present to MG53 molecules present is at least 2:1, when considering the two zinc ion binding sites present on each MG53 molecule. In some embodiments, the composition comprises a molar ratio of >2: 1 for the moles of Zn to moles of MG53.
[038] In some embodiments, the method of the invention further comprises adjunct administration of with at least one antioxidant, whereby said at least one antioxidant is administered prior to, along with, or after administration of MG53. Accordingly, the method of the invention can further comprise the step of administering at least one antioxidant to a subject. The molar ratio ofMG53 to antioxidant can be in the range of 0.01:1 to 10:1.
[039] In some embodiments, a subject is chronically administered MG53, at least one antioxidant, and at least one zinc salt. The invention also provides a composition comprising MG53, at least one antioxidant, and at least one zinc salt. The molar ratio of MG53 to antioxidant can be in the range of 0.01 : 1 to 10: 1.
[040] A composition of the invention can be administered one, two, three or more times per day. It can be administered daily, weekly, monthly, bimonthly, quarterly, semiannually, annually or even longer as needed. It can be administered every other day, five times per week, four times per week, three times per week, two times per week, once daily, twice daily, one to four times daily, continuously, or as frequently or infrequently as needed. The unit dose of each administration is independently selected upon each occurrence from the doses described in this specification or as determined to be therapeutically effective. All combinations of the dosing regimens described are contemplated to be within the scope of the invention.
[041] The composition may be administered one or more times over a treatment period of at least one week. The composition may be administered acutely or chronically. In some embodiments, the chronic administration is at least one weekly, at least once daily, two or more times daily, two or more times per week, or as needed at a dose of about 0.01 mg of MG53/kg of bodyweight to about 10 mg of MG53 /kg of bodyweight.
[042] The invention also provides the methods of treatment herein employing an enteric release composition comprising MG53, at least one enteric release material, and one or more pharmaceutical excipients. Following oral or peroral administration, the enteric release composition can be used to deliver MG53 to the gastrointestinal tract of a subject. The invention also provides a method of preventing, reversing or treating viral infection induced organ failure comprising administering to a subject an effective amount of said enteric release composition.
[043] The invention includes all combinations of the aspects, embodiments and sub embodiments disclosed herein. Other features, advantages and embodiments of the invention will become apparent to those skilled in the art by the following description, accompanying examples and appended claims.
BRIEF DESCRIPTION OF THE FIGURES
[044] The following drawings are part of the present specification and are included to further demonstrate certain aspects of the invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of the specific embodiments presented herein.
[045] FIG. 1 depicts a chart of the relative expression of MG53 in THP1 cells. Quantification of reduction in MG53 protein expression following SeV infection (data representative of three independent experiments at the 24 h timepoint and two independent experiments at the 48 h timepoint; mean ± SD; *** p < 0.001, **** p < 0.0001; One sample t-tests).
[046] FIG. 2. depicts a photograph of a gel comparing the effect of Sendai virus (SeV) and influenza virus H1N1 strain PR8 infection upon MG53 expression in THP1 cells.
[047] FIG. 3 depicts a chart of the percentage of SeV-GFP (green fluorescent protein labelled SeV) positive cells. Quantification of percentage of SeV-GFP positive cells (data representative of 4 independent experiments; mean ± SD; unpaired t-test).
[048] FIG. 4A depicts a chart of the percentage of initial body weight over time for mice infected with influenza virus. Mice were infected intranasally with influenza virus PR8 (10 TCID50). MG53 KO mice lost more weight and took longer to recover following PR8 infection compared to controls (n = 12 mice / group, mean ± SE; * = p < 0.05; Multiple t- tests).
[049] FIG. 4B depicts a chart of the viral titer in lung and heart tissue of wild type (WT) and knockout (KO) mice five days after infection with influenza virus. Lung and heart tissues were harvested from mice 5 days post infection. There was no significant difference in viral burden, as shown by comparable viral titers between WT and KO mice (n = 9 WT mice and 10 KO mice; mean±SE; unpaired t-test). Lungs were isolated at 5 days post infection and either fixed for histology or homogenized for viral titer.
[050] FIG. 5 depicts a graph of percent body mass versus time (day) for WT C57BL/6J mice (8 week old Jackson laboratories) intranasally infected with 100 TCID50 Influenza A virus PR8 in 50 ul sterile saline, then intravenously treated with saline as control and rhMG53 (2mg/kg, in saline). See Example 5. Mice were monitored daily for (A) body mass and (B) survival. All untreated infected mice lost weight until death (see FIG. 6); whereas all treated infected mice lost weight during the first half of the 2-week study period but ultimately regained full body weight by the end of the 2-week study period.
[051] FIG. 6 depicts a graph of the survival rate of the mice of FIG. 5. All untreated infected mice died by day-8; whereas almost all treated infected mice survived beyond the 2- week endpoint of the study.
[052] FIG. 7 depicts a chart of the viral titer of TCID50 in the lung tissue of the mice of FIG. 5 at day 7 post infection. There was no substantial difference in viral titer between treated and untreated infected mice.
[053] FIG. 8 depicts photographs of lung tissue after Trichrome staining after the mice of FIG. 5 were euthanized and lung tissues were collected. The Trichrome staining showed the extent of fibrosis (stained blue lesions) in the lungs. rhMG53 treatment (right) reduced the formation of viral infection-induced fibrosis as compared to saline control (left).
DETAILED DESCRIPTION OF THE INVENTION
[054] Hereinafter, preferred embodiments of the present invention will be described in detail with reference, as needed, to the accompanying figures.
[055] MG53 protein (also referred to as mitsugumin 53 or TRIM72) is known in the art. Unless specified otherwise, all embodiments of the invention comprising or employing “MG53” include all known forms of MG53. It also refers to recombinant human MG53 (rhMG53). As used herein and unless otherwise specified, the term MG53 (or MG53 protein) refers to the MG53 protein present as the native form, optimized form thereof, mutant thereof, derivative thereof or a combination of any two or more of said forms. Native MG53 contains 477 amino acids that are well conserved in different animal species. Methods of preparing and/or isolating MG53 are known: US 7981866, W02008/054561, W02009/073808, US2011/0202033, US2011/0287004, US2011/0287015, US2013/0123340,
WO20 11/142744, WO2012/061793, US 8420338, US 9139630, US 9458465, US 9494602, US2014/0024594, WO2012/134478, WO2012/135868, US2015/0110778, W02013/036610, US2012/0213737, WO2016/109638, the entire disclosures of which, including sequence information therein, are hereby incorporated by reference.
[056] The sequence listing information for native MG53, and variants or various forms thereof, is disclosed in US7981866 and US9139630, the entire disclosures of which, including sequence information therein, are hereby incorporated by reference. The sequence listing information for a cDNA that encodes optimized native human MG53, or a fragment thereof, is disclosed in US9139630, the entire disclosure of which, including sequence information therein, is hereby incorporated by reference.
[057] As used herein in reference to MG53, the term “mutant” means a recombinant form of MG53 having an amino acid change (replacement) of one, two, three or more amino acids
in the amino acid sequence of native MG53. Mutant forms of MG53 and methods of preparing the same are known: US2015/0361146, EP3118317, WO2015/131728, US9139630, the entire disclosures of which, including sequence information therein, are hereby incorporated by reference.
[058] As used herein the term “endogenous MG53”, refers to MG53 present in a subject prior to treatment with a composition or method according to the invention. As used herein, exogenous MG53 is nonendogenous MG53.
[059] As used herein, a subject at risk of viral infection is: a) a subject living in a geographical area within which mosquitos, in particular Aedes species ( Aedes egypti, Aedes albopictus ) mosquitos, live; b) a subject living with or near a person or people having viral infection; c) a subject having sexual relations with a person having a viral infection; d) a subject living in a geographical area within which ticks, in particular Ixodes species {Ixodes marx, Ixodes scapularis, or Ixodes cooke species) ticks, live; e) a subject living in a geographical area within which fruit bats live; f) subj ects living in a tropical region; g) subj ects living in Africa; h) subjects in contact with bodily fluids of other subjects having a viral infection; i) a child; or j) a subject with a weakened immune system. In some embodiments, the subject is a female, a female capable of getting pregnant, or a pregnant female.
[060] As used herein, the term “subj ecf ’ is taken to mean warm blooded creatures such as mammals, for example, cats, dogs, mice, guinea pigs, horses, bovine cows, sheep, and humans.
[061] The present inventors have unexpectedly discovered that virus infection-induced organ failure can be prevented, reversed or treated by administration of MG53 to a subject having a virus infection that causes organ failure.
[062] An in vitro viral assay was developed (Example 1) to determine whether MG53 expression is altered in THP1 cells upon infection with SeV (Sendai virus). We observed that SeV infection reduced MG53 protein expression by more than 50% (FIG. 1). This suggests that MG53 levels in cells are decreased during certain viral infections.
[063] We then compared the effects of SeV and influenza H1N1 strain PR8 infection on MG53 expression in THP1 cells (Example 2). We observed that SeV infection consistently led to reduced MG53 protein levels in THP1 cells, but influenza infection did not appear to induce a significant decrease in MG53 in THP1 cells (FIG. 2). This demonstrates that
alterations in MG53 levels is virus-specific and suggests that certain viruses may manipulate MG53 levels.
[064] We then determined whether endogenous MG53 affects the infection rate of cells by SeV (Example 3). shRNA was used to knock down the expression of MG53 in THP1 cells and, in doing so, confirmed that MG53 is also expressed in undifferentiated THP1 cells. Control shRNA (sh-control) and sh-MG53 knockdown THP1 cells were infected with SeV expressing GFP for 24 h. Cells were collected and examined by flow cytometry for GFP fluorescence, indicative of virus infection and virus protein production. We observed that knockdown of MG53 did not significantly affect the percentage of cells infected with virus as compared to sh-control cells, thereby indicating similar infection rates of sh-MG53 and sh- control THP1 cells (FIG. 3). This is indicative of the absence of a direct antiviral effect by MG53.
[065] We then determined whether MG53 plays a physiological role during in vivo viral infection, MG53 wild type (WT) and knockout (KO) mice were intranasally infected with influenza virus strain PR8 at a dose of 10 tissue culture infectious dose 50 (TCID50) (Example 4). This dose causes weight loss in WT mice, peaking around day 10, followed by a full recovery of body weight. Even though MG53 has no direct antiviral activity, we observed in MG53 KO mice a more severe decrease in weight following infection and a delayed recovery compared to WT mice (FIG. 4A). This suggests that MG53 provides defense against morbidity during respiratory infection with influenza virus.
[066] We then determined whether differences in virus replication and dissemination were responsible for worsened morbidity in KO mice. Virus titers were measured from lung and heart tissues 5 days post infection. WT and KO mice showed no significant difference in virus titers across tissues (FIG. 4B), suggesting comparable levels of viral replication and dissemination at this time point post infection. This is further evidence that MG53 does not possess a direct antiviral effect.
[067] We then determined whether exogenously administered MG53 might decrease mortality in mice infected with a lethal dose of influenza virus (Example 5). The mice were divided into two groups with each group receiving the same dose of influenza virus (100 TCID50 influenza A virus H1N1 strain PR8. The control group was not administered MG53, and the test group was administered exogenous MG53 (dose: 2mg/kg). The body weight of the mice was monitored (FIG. 5).
[068] After 8 days, all of the untreated mice had died, and all of the treated mice survived (FIG. 6). By day-14, all of the treated mice had completely recovered. Bodyweight of those mice was also recorded (FIG. 5). The treated mice were then euthanized. Post-mortem examination of the lung and heart of control and test mice was conducted. It was determined that the untreated control mice died of organ failure.
[069] The viral TCID50 titer for the lung tissue of all mice was calculated using the classic Reed & Muench method. Data demonstrated that saline and rhMG53 treated mice exhibited the same viral titer in the lung tissue (FIG. 7). This indicates that MG53 does not possess direct antiviral activity.
[070] Lungs were collected from the euthanized mice and stored in 4% PFA for histological analysis. Lung tissue Trichrome staining (Example 13) showed the lungs derived from mice treated with rhMG53 (FIG. 8: right) have less viral infection-induced fibrosis as compared to untreated saline control mice (FIG. 8: left).
[071] Since viral infection may induce long-term (chronic) organ failure by fibrosis, the invention also provides a method of mitigating viral infection-induced organ fibrosis, which might or might not be fatal. Contrary to what is suggested in the art, administration of exogenous MG53 is useful for preventing, reversing or treating long-term organ failure, in particular for mitigating viral infection induced organ fibrosis. A subject having a viral infection that induces organ fibrosis is administered MG53 according to a dosing regimen as described herein. As a result, virus infection-induced fibrosis in the subject’s organ is reduced (reversed) or progression of fibrosis is slowed or delayed compared to what might be expected (based upon comparison to an average population of subjects having said viral infection) had the subject not been administered MG53.
[072] The invention thus provides a method of preventing, reversing or treating organ failure, in particularly short-term or acute organ failure, in a subject infected with a virus that causes said organ failure. It also provides a method reducing the mortality rate in a population of subjects infected with a virus that causes said organ failure. It also provides a method of mitigating or reducing viral infection-induced organ fibrosis in a subject infected with a virus that causes organ fibrosis.
[073] If a clinician intends to treat a subject with a combination of MG53 (MG53- containing composition) and one or more other antiviral agents, and it is known that the organ failure-inducing viral infection, which the subject has, is at least partially therapeutically
responsive to treatment with said one or more other antiviral agents, then the present method invention comprises: administering to the subject in need thereof a therapeutically relevant dose of MG53 (MG53-containing composition or MG-53-expressing composition) and a therapeutically relevant dose of said one or more other antiviral agents, wherein the MG53 is administered according to a first dosing regimen and the one or more other antiviral agents is administered according to a second dosing regimen. In some embodiments, the first and second dosing regimens are the same. In some embodiments, the first and second dosing regimens are different.
[074] Methods of the invention include separate administration or coadministration of the MG53 with at least one other known antiviral composition, meaning the MG53 can be administered before, during or after administration of a known antiviral composition. In some embodiments, a composition for treating symptoms associated with the viral infection can also be administered to the subject to which MG53 is being administered. For example, medications used to treat inflammation, vomiting, nausea, headache, fever, diarrhea, nausea, hives, conjunctivitis, malaise, muscle pain, joint pain, seizure, or paralysis can be administered with or separately from the antiviral composition of the invention.
[075] The one or more other antiviral agents can be administered at doses and according to dosing regimens that are clinician-recognized as being therapeutically effective or at doses that are clinician-recognized as being sub-therapeutically effective. The clinical benefit and/or therapeutic effect provided by administration of a combination of MG53 and one or more other antiviral agents can be additive or synergistic, such level of benefit or effect being determined by comparison of administration of the combination to administration of the individual MG53 and one or more other antiviral agents. The one or more other antiviral agents can be administered at doses and according to dosing regimens as suggested or described by the Food and Drug Administration, World Health Organization, European Medicines Agency (E.M.E.A.), Therapeutic Goods Administration (TGA, Australia), Pan American Health Organization (PAHO), Medicines and Medical Devices Safety Authority (Medsafe, New Zealand) or the various Ministries of Health worldwide.
[076] Exemplary other antiviral agents that can be included in the method (and/or composition) of the invention for the treatment of viral infection-induced organ failure include antiretroviral agent, interferon alpha (IFN-a), zidovudine, lamivudine, cyclosporine A, CHOP with arsenic trioxide, sodium valproate, methotrexate, azathioprine, one or more symptom
alleviating dmg(s), steroid sparing drug, corticosteroid, cyclophosphamide, immunosuppressant, anti-inflammatory agent, Janus kinase inhibitor, tofacitinib, calcineurin inhibitor, tacrolimus, mTOR inhibitor, sirolimus, everolimus, IMDH inhibitor, azathioprine, leflunomide, my cophenol ate, biologic, abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, vedolizumab, monoclonal antibody, basiliximab, daclizumab, polyclonal antibody, nucleoside analogs, reverse transcriptase inhibitor, emtricitabine, telbivudine, abacavir, adefovir, didanosine, emtricitabine, entecavir, stavudine, tenofovir, azithromycin, macrolide-type antibiotic, protease inhibitor, interferon, immune response modifier, mRNA synthesis inhibitor, protein synthesis, inhibitor, thiazolide, CYP3A4 inhibitor, heterocyclic biguanidine, CCR5 receptor inhibitor, and combinations thereof. Therapies studied also include plasmapheresis and/or radiation. Antibodies to specific viruses may also be administered to a subject treated with the antiviral composition of the invention. Plasma obtained from the blood of survivors of a first viral infection can be administered to other subjects having the same type of viral infection, said other subjects also being administered the antiviral composition of the invention. For example, the plasma from a survivor of COVID-19 infection may be administered to another subject having a COVID-19 infection, said other subject also being administered the MG53 composition of the invention. [077] MG53 may be administered to a subject in many different forms.
[078] Since MG53 can be degraded by proteases in the GI tract or by the acidic conditions of the stomach, MG53 may be administered a probiotic composition whereby a safe microbe is engineered to express MG53. The probiotic composition is then administered orally (perorally) to a subject such that the microbe expresses MG53 in the GI tract of a subject. Exemplary probiotic compositions are disclosed in international application No. PCT/US2019/060684 to Ma, the entire disclosure of which is hereby incorporated by reference.
[079] As another means of providing MG53 to the intestinal tract downstream of the stomach, an enteric release (ER) composition comprising MG53 was developed. The ER composition comprises MG53, an enteric release pharmaceutical excipient, and a cyclodextrin. In particular embodiments, the ER composition comprises MG53, at least one enteric release polymer, and at least one cyclodextrin derivative.
[080] In particular embodiments, the enteric release polymer is a copolymer of methacrylic acid and methyl methacrylate. In particular embodiments, the enteric release polymer has a dissolution pH of > about 5, > about 5.5, > about 6, > about 6.5, or > about 7.
[081] In particular embodiments, the cyclodextrin derivative is water soluble. In particular embodiments, the cyclodextrin derivative is hydroxypropyl-beta-cyclodextrin.
[082] The amount of therapeutic compound (MG53) incorporated in each dosage form will be at least one or more unit doses and can be selected according to known principles of pharmacy. An effective amount of therapeutic compound is specifically contemplated. By the term "effective amount", it is understood that, with respect to, for example, pharmaceuticals, a pharmaceutically (therapeutically) effective amount is contemplated. A pharmaceutically effective amount is the amount or quantity of a drug or pharmaceutically active substance which is sufficient to elicit the required or desired therapeutic response, or in other words, the amount which is sufficient to elicit an appreciable biological response when administered to a patient.
[083] Suitable concentrations of MG53 in a liquid dosage form include at least 1 ng of MG53/ml, at least 5 ng of MG53/ml, at least 10 ng of MG53/ml, at least 25 ng of MG53/ml, at least 50 ng of MG53/ml, at least 75 ng of MG53/ml, at least 100 ng of MG53/ml, at least 250 ng of MG53/ml, at least 500 ng of MG53/ml, at least 750 ng of MG53/ml, at least 1 Dg of MG53/ml, at least 5 Dg of MG53/ml, at least 10 Dg of MG53/ml, at least 15 Dg of MG53/ml, atleast20 DgofMG53/ml, atleast25 DgofMG53/ml, atleast30 DgofMG53/ml, at least 50 Dg of MG53/ml, or at least 100 Dg of MG53/ml. Higher concentrations are also acceptable, particularly in view the efficacy dose-response trend observed for MG53. These doses can be administered on a frequency as described herein or as determined to be most effective.
[084] A dosing regimen includes a therapeutically relevant dose (or effective dose) of MG53 administered according to a dosing schedule. A therapeutically relevant dose, therefore, is a therapeutic dose at which a therapeutic response of the organ failure to treatment with a composition as described is observed and at which a subject can be administered said composition without an excessive amount of unwanted or deleterious side effects. A therapeutically relevant dose is non-lethal to a subject, even though it may cause some side effects in the patient. It is a dose at which the level of clinical benefit to a subject being administered said composition exceeds the level of deleterious side effects experienced by the
subject due to administration of said composition or component(s) thereof. A therapeutically relevant dose will vary from subject to subject according to a variety of established pharmacologic, pharmacodynamic and pharmacokinetic principles.
[085] A therapeutically relevant dose can be administered according to any dosing regimen typically used in the treatment of viral infection. A therapeutically relevant dose can be administered once, twice, thrice or more daily. It can be administered every other day, every third day, every fourth day, every fifth day, semiweekly, weekly, biweekly, every three weeks, every four weeks, monthly, bimonthly, semimonthly, every three months, every four months, semiannually, annually, or according to a combination of any of the above to arrive at a suitable dosing schedule. For example, a therapeutically relevant dose can be administered one or more times daily (up to 10 times daily for the highest dose) for one or more weeks.
[086] Suitable doses of MG53 that can be administered to a subject in one or more dosage forms include at least 1 ng of MG53, at least 5 ng of MG53, at least 10 ng of MG53, at least 25 ng of MG53, at least 50 ng of MG53, at least 75 ng of MG53, at least 100 ng of MG53, at least 250 ng of MG53, at least 500 ng of MG53, at least 750 ng of MG53, at least 1 Dg of MG53, at least 5 Dg of MG53, at least 10 Dg of MG53, at least 15 Dg of MG53, at least 20 □ g of MG53, at least 25 Dg of MG53, at least 30 Dg of MG53, at least 50 Dg of MG53, or at least 100 Dg of MG53. Such doses can be on a total body weight basis or a per kg of body weight basis.
[087] The dose of exogenous MG53 can be as low as about 1 microg per kg of body weight up to about 1000 microg per kg of body weight.
[088] The term "unit dosage form" is used herein to mean a dosage form containing a quantity of the MG53, said quantity being such that one or more predetermined units may be provided as a single therapeutic administration.
[089] The dosage form is independently selected at each occurrence from the group consisting of liquid solution, suspension, tablet, pill, vial, powder, granule, bead, caplet, capsule, sachet or powder.
[090] Compositions and dosage forms of the invention can further comprise one or more pharmaceutically acceptable excipients. Dosage forms can comprise one or more excipients independently selected at each occurrence from the group consisting of acidic agent, alkaline agent, buffer, tonicity modifier, osmotic agent, water soluble polymer, water-swellable
polymer, thickening agent, complexing agent, chelating agent, penetration enhancer. Suitable excipients include U.S.F.D.A. inactive ingredients approved for use in parenteral or oral formulations (dosage forms), such as those listed in the U.S.F.D.A.’s “Inactive Ingredients Database (available on the following website: https://www.fda.gov/Drugs/InformationOnDrugs/ucml l3978.htm: Oct. 2018), the entire disclosure of which is hereby incorporated by reference.
[091] As used herein, an acidic agent is a compound or combination of compounds that comprises an acidic moiety. Exemplary acidic agents include organic acid, inorganic acid, mineral acid and a combination thereof. Exemplary acids include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfonic acid, sulfamic acid, phosphoric acid, or nitric acid or others known to those of ordinary skill; and the salts prepared from organic acids such as amino acids, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2- acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isethionic acid, others acids known to those of ordinary skill in the art, or combinations thereof.
[092] As used herein, an alkaline agent is a compound or combination of compounds that comprises an alkaline moiety. Exemplary alkaline agents include primary amine, secondary amine, tertiary amine, quaternary amine, hydroxide, alkoxide, and a combination thereof. Exemplary alkaline agents include ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, diethanolamine, monobasic phosphate salt, dibasic phosphate salt, organic amine base, alkaline amino acids and trolamine, others known to those of ordinary skill in the art, or combinations thereof.
[093] Exemplary excipients (inactive ingredients as defined by the U.S.F.D.A.) that can be included in dosage forms of the invention include, by way of example and without limitation, water, benzalkonium chloride, glycerin, sodium hydroxide, hydrochloric acid, boric acid, hydroxyalkylphosphonate, sodium alginate, sodium borate, edetate disodium, propylene glycol, polysorbate 80, citrate, sodium chloride, polyvinylalcohol, povidone, copovidone, carboxymethylcellulose sodium, Dextrose, Dibasic Sodium Phosphate, Monobasic Sodium Phosphate, Potassium Chloride, Sodium Bicarbonate, Sodium Citrate,
Calcium Chloride, Magnesium Chloride, stabilized oxychloro complex, Calcium Chloride Dihydrate, Erythritol, Levocamitine, Magnesium Chloride Hexahydrate, Sodium Borate Decahydrate, Sodium Citrate Dihydrate, Sodium Lactate, Sodium Phosphate (Mono- and Dibasic-), Polyethylene Glycol 400, Hydroxypropyl Guar, Polyquatemium-1, Zinc Chloride, white petrolatum, mineral oil, hyaluronic acid, artificial tear, or combinations thereof.
[094] One or more antioxidants can be included in a composition or dosage form of the invention. Exemplary antioxidants include SS-31, NAC, glutathione, selenium, vitamin A, vitamin C, vitamin E, co-enzyme Q10, resveratrol, other GRAS antioxidant, or a combination of two or more thereof.
[095] One or more zinc salts can be included in a composition or dosage form of the invention. Such zinc salt(s) may also be administered to a subj ect receiving exogenous MG53 or expressed MG53. Pharmaceutically acceptable zinc salts include Zinc gluconate, Zinc acetate, Zinc sulfate, Zinc picolinate, Zinc orotate, Zinc citrate, and other such salts comprising a zinc cation and organic or inorganic anion(s).
[096] It should be understood, that compounds used in the art of pharmaceutical formulations generally serve a variety of functions or purposes. Thus, if a compound named herein is mentioned only once or is used to define more than one term herein, its purpose or function should not be construed as being limited solely to that named purpose(s) or function(s).
[097] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the compound is modified by making an acid or base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and others known to those of ordinary skill. The pharmaceutically acceptable salts can be synthesized from the parent therapeutic compound which contains a basic or acidic moiety by conventional chemical methods. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
[098] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[099] The therapeutically acceptable dose, maximum tolerated dose (MTD), and minimally effective dose (MED) for each of said active ingredients is well known and set forth in the respective U.S.F.D.A. approved product package insert for each said active ingredients. [0100] A composition, dosage form or formulation of the invention can include one, two or more active ingredients in combination with MG53. The dose of each said active ingredient in said composition, dosage form or formulation of the invention will be a therapeutically effective dose including and above the MED and including and below the MTD.
[0101] In some embodiments, the combination treatment of MG53 with another active ingredient provides at least additive therapeutic efficacy. In some embodiments, said combination provides synergistic therapeutic efficacy. In some embodiments, MG53 reduces the occurrence of, reduces the level of, or eliminates adverse events caused by the other active ingredient.
[0102] The acceptable concentrations of said excipients are well known in the art and specific concentrations (amounts) thereof are set forth in the package insert or package label of known commercial products containing the same.
[0103] It should be understood that compounds used in the art of pharmaceutics may serve a variety of functions or purposes. Thus, if a compound named herein is mentioned only once or is used to define more than one term herein, its purpose or function should not be construed as being limited solely to that named purpose(s) or function(s).
[0104] As used herein, the terms “about” or “approximately” are taken to mean a variation or standard deviation of ±10%, ±5%, or ±1% of a specified value. For example, about 20 mg is taken to mean 20 mg ±10%, which is equivalent to 18-22 mg.
[0105] As used herein, the term “prodrug” is taken to mean a compound that, after administration, is converted within a subject’s body, e.g. by metabolism, hydrolysis, or biodegradation, into a pharmacologically active drug. The prodrug may be pharmacologically active or inactive. For example, a prodrug of MG53 (native or mutant) would be converted to the native form or mutant form, respectively, of MG53. The term “precursor” may also be used instead of the term “prodrug”.
[0106] As used herein, the term “derivative” is taken to mean: a) a chemical substance that is related structurally to a first chemical substance and theoretically derivable from it; b) a compound that is formed from a similar first compound or a compound that can be imagined to arise from another first compound, if one atom of the first compound is replaced with another atom or group of atoms; c) a compound derived or obtained from a parent compound and containing essential elements of the parent compound; or d) a chemical compound that may be produced from first compound of similar structure in one or more steps. For example, a derivative may include a deuterated form, oxidized form, dehydrated, unsaturated, polymer conjugated or glycosilated form thereof or may include an ester, amide, lactone, homolog, ether, thioether, cyano, amino, alkylamino, sulfhydryl, heterocyclic, heterocyclic ring-fused, polymerized, pegylated, benzylidenyl, triazolyl, piperazinyl or deuterated form thereof. [0107] In the examples below, ranges are specified for the amount of each ingredient. Ranges including “0” as the lowest value indicate an optional ingredient. The lower limit “>0” indicates the respective material is present.
[0108] Compositions with quantities of ingredients falling within the compositional ranges specified herein were made. Compositions of the invention comprising quantities of ingredients falling within the compositional ranges specified herein operate as intended and as claimed.
[0109] In view of the above description and the examples below, one of ordinary skill in the art will be able to practice the invention as claimed without undue experimentation. The foregoing will be better understood with reference to the following examples that detail certain procedures for the preparation and use of compositions according to the present invention. All references made to these examples are for the purposes of illustration. The following examples should not be considered exhaustive, but merely illustrative of only a few of the many embodiments contemplated by the present invention. The methods described herein can be followed to prepare and use compositions of the invention and to practice methods of the invention.
[0110] MG53 was kindly provided by TRIM-edicine, Inc. (1275 Kinnear RD, Columbus OH 43212-1155, U.S.A.). We thank Dr. Wayne Chen for providing the doxycycline inducible RyR2 expressing HEK293 cells, Drs. Juan Moliva and Jordi Torrelles for providing the primary human blood monocyte-derived macrophage protein lysates, and Dr. Dominique Garcin for providing SeV-GFP.
EXAMPLE 1
In vitro assay in THP1 cells: SeV
[0111] Sendai virus (SeV) expressing GFP, SeV strain Cantell, PR8 were propagated in embryonated chicken eggs and titered on LLCMK2 cells for SeV and MDCK cells for influenza virus. SeV-GFP and SeV infections were allowed to proceed for 24 or 48 hours using multiplicity of infections (MOIs) of 2 and 5 respectively. 24 hrs post SeV-GFP infection, THP1 cells were washed in PBS and fixed using 4% paraformaldehyde. Cells were washed, resuspended in PBS, and analyzed with a FACSCanto II flow cytometer (BD Biosciences) to determine the percentage of GFP positive cells. Data was analyzed using FlowJo software.
EXAMPLE 2
In vitro assay in THP1 cells: SeV and H1N1 influenza [0112] Sendai virus (SeV) expressing GFP, SeV strain Cantell, and influenza virus strain PR8 were propagated in embryonated chicken eggs and titered on LLCMK2 cells for SeV and MDCK cells for influenza virus. SeV-GFP and SeV infections were allowed to proceed for 24 or 48 hours using multiplicity of infections (MOIs) of 2 and 5 respectively. 24 hrs post SeV-GFP infection, THP1 cells were washed in PBS and fixed using 4% paraformaldehyde. Cells were washed, resuspended in PBS, and analyzed with a FACSCanto II flow cytometer (BD Biosciences) to determine the percentage of GFP positive cells. Data was analyzed using FlowJo software.
EXAMPLE 3
Knockdown of MG53 in THP1 cells
[0113] Control shRNA (SEQ ID 1: 5’-GACTGACATGTCAAGCTGTAC-3’) and MG53 shRNA (SEQ ID 2: 5'- GAAGAGTGTGGCTGTGCTGGAGCATCAGC-3 ’) were ligated into pKLO-mcherry-puro vector. In brief, HEK293-FT cells were transfected with packaging, envelope, and target plasmids. Media was changed 18 hours after transfection, followed by collection of virus-containing media 48 hours later. Virus-containing media was centrifuged at 1200 x g for 5 min and filtered with 0.45pm filters. THP1 cells were then incubated with viral media. After 24 hrs, media was replaced, and cells were allowed 48 hrs to recover. Following recovery, cells were selected for using puromycin (1.0 pg/mL), and subsequently cultured in RPMI-1640 media supplemented with puromycin (0.5 pg/mL), to generate sh- control and sh-MG53 THP1 cells.
EXAMPLE 4
In vivo model: MG53 WT vs KO mice treated with influenza [0114] MG53 knockout mice were generated in the 129Sl/SvlmJ strain of mice. All mice were housed and handled following IACUC approved protocols. Murine intranasal influenza virus infections were carried out in 12-week-old male MG53 wild type and knockout mice. Animals were anesthetized using isoflurane and were intranasally infected with influenza virus strain A/PR/8/34 (H1N1) (PR8) at a dose of 10 tissue culture infectious dose 50 (TCID50) in 50 pL clinical grade saline. Mice were monitored daily and weights were recorded. Animals were euthanized at either day 5 post infection or at the experimental endpoint when they recovered to normal body weight. After animals were sacrificed, lungs and hearts were collected for viral titers, cytokine measurements, and histology.
EXAMPLE 5
Mortality in wt mice infected with influenza
[0115] Eight-week-old WT C57BL/6J mice (Jackson laboratories) were intranasally infected with 100 TCID50 Influenza A virus A/PR/8/34 (H1N1) in 50 ml sterile saline. Mice were monitored daily for body mass and survival. Mice reaching 30% body mass loss with hunched posture and lack of movement were considered moribund and removed from the study.
EXAMPLE 6 THP1 cell culture
[0116] THP1 cells were purchased from ATCC and cultured in RPMI-1640 media supplemented with L-Glutamine and sodium pyruvate (Sigma R8758) in addition to 10% fetal bovine serum and 1% penicillin / streptomycin in a 5% C02 incubator. THP1 cells were differentiated using 100 ng/mL PMA (Sigma PI 585) for 48 hrs. HEK293 and HEK293FT cells were obtained from ATCC and cultured using Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a 5% C02 incubator. HEK293-RyR2 cells were provided by Dr. Wayne Chen47. These cells possess doxycycline-inducible RyR2 expression, which enables spontaneous calcium oscillation in response to elevated extracellular calcium via store-overload induced calcium release. Cells were cultured using DMEM supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin in a 5% CO2 incubator. Treatment with doxycycline (lpg/mL) for 24 hrs was used to induce RyR expression.
EXAMPLE 7
Western Blot analyses
[0117] Cells and murine skeletal muscle were lysed in radio-immunoprecipitation assay lysis buffer (Alfa Aesar, J63306) containing protease and phosphatase inhibitors. Cellular debris was pelleted via centrifugation and supernatants were collected for protein quantification by Bradford assay. Samples were prepared in 2x Laemlli sample buffer and separated on SDS-PAGE gels via electrophoresis, followed by wet transfer onto PVDF membrane. Membranes were blocked in 5% milk in TBS-T and probed with antibodies against MG53 (custom-made rabbit monoclonal antibody), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology (CST) catalog #2118), p65 (CST 8242), phospho-p65 (CST 3033), or RyR (Invitrogen MA3925).
EXAMPLE 8
Oral Dosage Form of rhMG53 and EUDRAGIT S-100 [0118] rhMG53 is provided by TRIM-edicine, Inc. (Columbus, OH). EUDRAGIT S-100 (Poly(methacylic acid-co-methyl methacrylate) 1:2) is provided by EVONIK (https://healthcare.evOnik.com/product/health-care/en/). The following procedure is used to prepare beads.
[0119] In a 100 mL beaker, add 35 mL water, and stir. While stirring add Eudragit S-100 powder (1.4 g), then and I2NNH4OH (0.82 mL). Add 2-hydroxypropyl)- -cyclodextrin (0.24 g) to a 10 mL water (CD: 24 mg/mL). Prepare a solution of MG53 (70 mg in -15.5 mL PBS) at a pH 8. To this solution, add 10 mL of the CD solution and 10 mL of water for a total volume of 35.55 mL. Mix the MG53/CD solution with the Eudragit solution while stirring. [0120] Spray dry the resulting suspension to form the powdered dosage form containing MG53 (70 mg), EUDRAGIT (1.4 g), salts (130 mg), and CD (0.24 g) for a total solids content of 1.77 g or a MG53-loading of 40 mg/g of solid (4% loading). Spray drying conditions used: nozzle size- 0.6 mm; air speed- 0.3 m3/min; air outlet temp: 38 C; room temperature: 24 C; room humidity: 53%.
[0121] The powder can be included in a capsule, caplet, tablet or other oral dosage form.
EXAMPLE 9
Preparation of MG53 -containing Enteric Release Composition [0122] The enteric release formulation comprises MG53, hydroxypropyl-beta-cyclodextrin (HP-b-CD), and methacrylic acid / methyl methacrylate anionic copolymer (EUDRAGIT S 100; dissolution in water at pH above 7.0). The following procedure was used.
1. In a 100 mL beaker, added 35 mL water;
2. weighed 1.4 g Eudragit S-100 powder and added to the H2O above while stirring;
3. added 0.82 mL of 12N NH4OH and stirred continuously for half an hour while periodically checking pH;
4. weighed 0.24 g of 2-hydroxypropyl)-P-cyclodextrin and added to a vial containing 10 mL water (CD: 24 mg/mL);
5. added 70 mg MG53 to 15.5 mL PBS at pH 8;
6. mixed the HP-b-CD solution with the MG53 -containing solution and add water to a total volume of 35.55 mL;
7. added the MG53/CD solution to the 35 mL Eudragit-containing solution while stirring, and added 1 mL of water;
6. spray dried the MG53/CD/EUDRAGIT solution according to Example 11;
[0123] The resulting enteric release composition contained: MG53 70 mg; Eudragit 1.4 g; salts: 15.5/2*17 mg/mL=130 mg; CD 0.24 g.
EXAMPLE 10
Determination of In-vitro Release Profile
[0124] A known amount of powdered samples of MG53 containing enteric release composition (made according to Example 9) was dispersed in pH 2 (0.01N HC1) solution for 2 hrs, followed by addition of NasPCri solution (9.7 g in 112.8 mL H2O; to pH 6.5), then followed by addition of same NasPCri solution to pH 7.5. At different time points, the released MG53 solution was centrifuged at 17,000g for 20 min, filtered through 0.22 um filter, and the
absorbance at 280 nm was measured (n=2 per time points). The release experiments were performed in an orbital shaker at 37 °C and 150 rpm.
EXAMPLE 11
Spraying drying of MG53/CD/EETDRAGIT mixture [0125] The MG53/CD/EEIDRAGIT mixture was produced by spray-drying using the laboratory scale ProCept 4M8-TriX spray-dryer (Zelzate, Belgium). Drug-polymer solutions were prepared in the binary solvent mixture of interest DCM/EtOH 2:1 (v/v) at 50 mg/mL. The feed solution flow rate was adjusted at 5 g/min. An atomizing air pressure of 0.65 bars was applied to a 1.2 mm bifluid nozzle to create a spray. The drying gas airflow was set at 0.35 m3/min and maintained at 65 °C. The lateral cooling air was kept constant at 100 L/min and dried particles were separated from the exhaust air within the medium cyclone (height/diameter of 242 mm/60 mm). After processing, the spray-dried material was stored in a vacuum oven for 48 h before analysis to eliminate the last traces of residual solvent.
EXAMPLE 12
Co-immunoprecipitation
[0126] Tissue and cells were lysed in radio-immunoprecipitation (IP) assay lysis buffer and assayed for protein concentration as stated above. 20 pL of magnetic protein G beads (per IP sample) were washed in PBS three times and conjugated to 2 pg (per IP sample) of antibody (MG53, RyR, Mouse and Rabbit IgG) for 2 hours at room temperature while rocking. Bead- antibody conjugates were then washed 2 times with PBS and once with lysis buffer. 1 mg of protein lysate was added to beads and then samples were incubated at 4°C overnight while rocking. The following day, samples were washed 3 times in PBS and protein was eluted with 4% SDS and 2x Laemlli sample buffer. IP samples were then analyzed following the western blotting protocol stated earlier.
EXAMPLE 13 Masson's Trichrome Staining
[0127] The following procedure was used to determine the level of fibrosis in lung tissue.
1. Deparaffmize the paraffin embedded lung tissue block and rehydrate through 100% alcohol, 95% alcohol 70% alcohol. Wash in distilled water.
2. For Formalin fixed tissue, re-fix in Bouin's solution for 1 hour at 56 C to improve staining quality although this step is not absolutely necessary.
3. Rinse in running tap water for 5-10 minutes to remove the yellow color. Stain in Weigerf s iron hematoxylin working solution for 10 minutes.
4. Rinse in running warm tap water for 10 minutes.
5. Wash in distilled water.
6. Stain in Biebrich scarlet-acid fuchsin solution for 10-15 minutes. Solution can be saved for future use.
7. Wash in distilled water.
8. Differentiate in phosphomolybdic-phosphotungstic acid solution for 10-15 minutes or until collagen is not red.
9. Transfer sections directly (without rinse) to aniline blue solution and stain for 5-10 minutes. Rinse briefly in distilled water and differentiate in 1% acetic acid solution for 2-5 minutes.
10. Wash in distilled water.
11. Dehydrate very quickly through 95% ethyl alcohol, absolute ethyl alcohol (these step will wipe off Biebrich scarlet-acid fuchsin staining) and clear in xylene.
12. Mount with resinous mounting medium.
EXAMPLE 14
Treatment of COVID-19 (SARS-COV-2) infection in a subject Method A. MG53 Composition therapy
A subject presenting with COVID-19 virus infection is prescribed MG53 composition, and therapeutically relevant doses are administered to the subject according to a prescribed dosing regimen for a period of time. The subject’s level of therapeutic response (in terms of performance of one or more organs) is determined periodically. If the level of therapeutic response is too low at one dose, then the dose is escalated according to a predetermined dose escalation schedule until the desired level of therapeutic response in the subject is achieved. Treatment of the subject with MG53 is continued as needed and the dose or dosing regimen can be adjusted as needed until the patient reaches the desired clinical endpoint.
Method B. Combination therapy: MGS 3 and antiviral agent
Method A, above, is followed except that the subject is prescribed and administered one or more other antiviral agents for the treatment of COVID-19 virus infection or symptoms thereof. Then one or more other antiviral agents can be administered before, after or with the MG53. Dose escalation (or de-escalation) of the one or more other antiviral agents can also be done.
[0128] All data are expressed as mean ± S.D. Groups were compared by Student’ s t test and analysis of variance for repeated measures. A value of p<0.05 was considered significant. [0129] For any range herein, the upper and lower limits thereof are considered as being part of the range. Moreover, all integer and fractional values within said ranges are also considered as being within said range. Accordingly, all integers and fractional values within each specified range are hereby incorporated by reference.
[0130] All values disclosed herein may have standard technical measure error (standard deviation) of ± 10%. The term “about” or “approximately” is intended to mean ±10%, ±5%, ±2.5% or ±1% relative to a specified value, i.e. “about” 20% means 20±2%, 20±1%, 20±0.5% or 20±0.25%. The term “majority” or “major portion” is intended to mean more than half, when used in the context of two portions, or more than one-third, when used in the context of three portions. The term “minority” or “minor portion” is intended to mean less than half, when used in the context of two portions, or less than one-third, when used in the context of three portions. It should be noted that, unless otherwise specified, values herein concerning pharmacokinetic or dissolution parameters are typically representative of the mean or median values obtained.
[0131] The above is a detailed description of particular embodiments of the invention. It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims. All of the embodiments disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.
Claims
1) A method of preventing viral infection-induced organ failure, the method comprising administering to a subject, infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure.
2) A method of preventing viral infection-induced organ failure, the method comprising administering to a subject, at risk of being infected with a virus that induces organ failure, one or more doses of MG53, thereby preventing said organ failure.
3) A method of reversing viral infection-induced organ failure, the method comprising administering to a subject, exhibiting (indicated with) viral infection-induced organ failure, one or more doses of MG53, thereby reversing said organ failure.
4) A method of reducing the mortality rate in a population of subjects having a viral infection that causes mortality due to organ failure, the method comprising administering to subjects of said population one or more doses of MG53, thereby reducing the mortality rate in said population of subjects.
5) A method of mitigating (e.g. ameliorating, treating, curing) virus-infection induced organ fibrosis, which may or may not be fatal, the method comprising administering to a subject, infected with a virus that induces organ fibrosis, one or more doses of MG53, thereby mitigating fibrosis of one or more organs of said subject.
6) The method according to any one of the above claims, wherein a) said organ failure is short-term or acute organ failure, meaning organ failure that occurs over a period of hours, days, weeks or up to about three months; or b) said organ failure is long-term or chronic organ failure, meaning organ failure that occurs over a period of about three months or more.
7) The method according to any one of the above claims, wherein said virus that induces organ failure and/or causes mortality is selected from the group consisting of positive-sense single-stranded RNA virus ((+)-ss-envRNAV), negative-sense single- stranded RNA virus ((-)-ss-envRNAV), double-stranded DNA virus (ds-DNAV), and positive-sense RNA via DNA virus.
8) The method according to any one of the above claims, wherein said organ is selected from the group consisting of the respiratory system, heart, lung, kidney, liver, gastrointestinal system.
9) The method according to any one of the above claims, wherein said MG53 is administered acutely, chronically, or a combination thereof.
10) The method according to any one of the above claims, wherein said MG53 is administered in one or more dosage forms exhibiting one or more release profiles selected from the group consisting of immediate release, rapid release, extended release, sustained release, controlled release, enteric release, and a combination of any thereof.
11) The method according to any one of the above claims, wherein said MG53 is administered orally, by injection, intravenously, intraarterially, subcutaneously, intramuscularly, rectally, by infusion, directly to a target organ, and/or transdermally.
12) The method according to any one of the above claims, wherein said MG53 is recombinant human MG53.
13) The method according to any one of the above claims, wherein said MG53 is exogenous MG53.
14) The method according to any one of the above claims, wherein MG53 is a native recombinant human MG53 or mutant recombinant human MG53.
15) The method according to any one of the above claims further comprising the step of administering one or more therapeutically relevant doses of one or more antiviral agents to said subject.
16) The method of claim 15, wherein administration of MG53 and said one or more antiviral agents is separate, overlapping, sequential, or simultaneous.
17) A method of preventing viral infection-induced organ failure as described herein.
18) A method of reversing viral infection-induced organ failure as described herein.
19) A method of reducing the mortality rate in a population of subjects having a viral infection that causes mortality due to organ failure as described herein.
20) A method of mitigating (e.g. ameliorating, treating, curing) virus-infection induced organ fibrosis, which may or may not be fatal, as described herein.
21) A composition as described herein.
22) A MG53 -containing composition as described herein.
23) A MG53 -containing and antiviral agent-containing composition as described herein.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20931478.0A EP4135744A4 (en) | 2020-04-14 | 2020-04-14 | Prevention and treatment of viral infection-induced organ failure |
CN202080102017.1A CN115835877A (en) | 2020-04-14 | 2020-04-14 | Prevention and treatment of organ failure caused by viral infection |
PCT/US2020/028112 WO2021211098A1 (en) | 2020-04-14 | 2020-04-14 | Prevention and treatment of viral infection-induced organ failure |
US17/184,781 US11197912B2 (en) | 2020-04-14 | 2021-02-25 | Prevention and treatment of viral infection and viral infection-induced organ failure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/028112 WO2021211098A1 (en) | 2020-04-14 | 2020-04-14 | Prevention and treatment of viral infection-induced organ failure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/184,781 Continuation-In-Part US11197912B2 (en) | 2020-04-14 | 2021-02-25 | Prevention and treatment of viral infection and viral infection-induced organ failure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021211098A1 true WO2021211098A1 (en) | 2021-10-21 |
Family
ID=78005784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/028112 WO2021211098A1 (en) | 2020-04-14 | 2020-04-14 | Prevention and treatment of viral infection-induced organ failure |
Country Status (4)
Country | Link |
---|---|
US (1) | US11197912B2 (en) |
EP (1) | EP4135744A4 (en) |
CN (1) | CN115835877A (en) |
WO (1) | WO2021211098A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021015894A1 (en) * | 2019-07-25 | 2021-01-28 | Trim-Edicine, Inc. | Composition for and method of improving tissue performance |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120213737A1 (en) * | 2011-02-18 | 2012-08-23 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for therapeutic membrane repair |
US20130123340A1 (en) * | 2010-05-11 | 2013-05-16 | Peking University, Office Of Technology Transfer | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
US20140024594A1 (en) * | 2011-03-31 | 2014-01-23 | Noah Weisleder | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
WO2016109638A1 (en) * | 2014-12-30 | 2016-07-07 | Rutgers, The State University Of New Jersey | Compositions and methods to prevent and repair acute kidney injury |
US20180236024A1 (en) * | 2015-02-26 | 2018-08-23 | Stc.Unm | Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7542287B2 (en) | 2005-09-19 | 2009-06-02 | Chatsworth Products, Inc. | Air diverter for directing air upwardly in an equipment enclosure |
US9139630B2 (en) | 2006-07-11 | 2015-09-22 | Rutgers, The State University Of New Jersey | Compositions and methods for preparing recombinant MG53 and methods for optimizing same |
US20110202033A1 (en) | 2006-07-11 | 2011-08-18 | Noah Weisleder | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
US7981866B2 (en) | 2006-07-11 | 2011-07-19 | University Of Medicine And Dentistry Of New Jersey | MG53 compositions and methods of use |
US20150110778A1 (en) * | 2006-07-11 | 2015-04-23 | Rutgers, The State University of New Jersery | Compositions comprising mg53 and methods for the treatment and prevention of airway injury |
CN101557818A (en) | 2006-10-03 | 2009-10-14 | 新泽西医科和牙科大学 | ATAP peptides, nucleic acids encoding the same and associated methods of use |
KR20100099249A (en) | 2007-12-04 | 2010-09-10 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Compositions and methods to modulate cell membrane resealing |
US8603992B2 (en) | 2008-07-18 | 2013-12-10 | University Of Medicine And Dentistry Of New Jersey | Compositions comprising MG29 nucleic acids, polypeptides, and associated methods of use |
US8603993B2 (en) | 2009-06-05 | 2013-12-10 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods modulating MG29 for the treatment of diabetes |
AU2010254820B2 (en) | 2009-06-05 | 2014-01-30 | Rutgers, The State University Of New Jersey | Compositions and methods modulating MG29 for the treatment of diabetes |
US8420338B2 (en) | 2010-11-05 | 2013-04-16 | University Of Medicine And Dentistry Of New Jersey | Serum MG53 as a diagnostic marker for tissue injury |
WO2012134478A1 (en) | 2011-03-31 | 2012-10-04 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
CN104066452A (en) * | 2011-09-07 | 2014-09-24 | 新泽西医科和牙科大学 | Compositions comprising MG53 and methods for the treatment and prevention of airway injury |
CN104877971B (en) * | 2015-06-02 | 2018-03-30 | 汉恒生物科技(上海)有限公司 | A kind of gland relevant viral vector for the carrying MG53 genes that can alleviate mouse symptoms of heart failure |
WO2020132647A1 (en) * | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
EP3982999A4 (en) * | 2019-06-17 | 2023-07-19 | Trim-Edicine, Inc. | Composition for and method of treating hepatic tissue injury |
WO2021096479A1 (en) * | 2019-11-11 | 2021-05-20 | Trim-Edicine, Inc. | Treatment for inflammatory bowel disease and radiation-induced intestinal injury |
-
2020
- 2020-04-14 CN CN202080102017.1A patent/CN115835877A/en active Pending
- 2020-04-14 WO PCT/US2020/028112 patent/WO2021211098A1/en unknown
- 2020-04-14 EP EP20931478.0A patent/EP4135744A4/en active Pending
-
2021
- 2021-02-25 US US17/184,781 patent/US11197912B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130123340A1 (en) * | 2010-05-11 | 2013-05-16 | Peking University, Office Of Technology Transfer | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
US20120213737A1 (en) * | 2011-02-18 | 2012-08-23 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for therapeutic membrane repair |
US20140024594A1 (en) * | 2011-03-31 | 2014-01-23 | Noah Weisleder | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
WO2016109638A1 (en) * | 2014-12-30 | 2016-07-07 | Rutgers, The State University Of New Jersey | Compositions and methods to prevent and repair acute kidney injury |
US20180236024A1 (en) * | 2015-02-26 | 2018-08-23 | Stc.Unm | Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
Non-Patent Citations (4)
Title |
---|
BYTYÇI IBADETE, BAJRAKTARI GANI: "Mortality in heart failure patients", ANADOLU KARDIYOLOJI DERGISI/THE ANATOLIAN JOURNAL OF CARDIOLOGY, vol. 15, no. 1, 22 January 2015 (2015-01-22), pages 63 - 68, XP055864614, ISSN: 1302-8723, DOI: 10.5152/akd.2014.5731 * |
LEE JONG K., SYED H. E. ZAIDI, PETER LIU, FAYEZ DAWOOD, ALEXANDER Y. L.CHEAH, WEN-HU WEN, YURIKO SAIKI, MARLENE RABINOVITCH: "A Serine Elastase Inhibitor Reduces Inflammation and Fibrosis and Preserves Cardiac Function After Experimentally-Induced Murine Myocarditis", NATURE MEDICINE, vol. 4, no. 12, 1 December 1998 (1998-12-01), pages 1383 - 1391, XP055864617, DOI: 10.1038/3973 * |
SARASTE ANTTI, KYTÖ VILLE, SARASTE MARKKU, VUORINEN TYTTI, HARTIALA JAAKKO, SAUKKO PEKKA: "Coronary flow reserve and heart failure in experimental coxsackievirus myocarditis. A transthoracic Doppler echocardiography study", AMERICAN JOURNAL OF PHYSIOLOGY HEART AND CIRCULATORY PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 291, no. 2, 1 August 2006 (2006-08-01), US , pages H871 - H875, XP055864618, ISSN: 0363-6135, DOI: 10.1152/ajpheart.01375.2005 * |
See also references of EP4135744A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20210315968A1 (en) | 2021-10-14 |
CN115835877A (en) | 2023-03-21 |
US11197912B2 (en) | 2021-12-14 |
EP4135744A1 (en) | 2023-02-22 |
EP4135744A4 (en) | 2024-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102265798B1 (en) | Antiviral composition for treatment of infection associated with coronavirus | |
JP2023521051A (en) | Inhalation Formulations of 1'-Cyano-Substituted Carbanucleoside Analogues | |
RU2524304C2 (en) | Application of acetylsalicylic acid salt for treatment of viral infections | |
KR20210035339A (en) | Thiazolide compounds for treating viral infections | |
KR20220150348A (en) | PLD for use in combination in the treatment of coronavirus | |
US11197912B2 (en) | Prevention and treatment of viral infection and viral infection-induced organ failure | |
JP2023531872A (en) | Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis | |
TW202203946A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
JP2023517536A (en) | Compounds for use in inflammatory conditions | |
JP2019504040A (en) | Treatment of moderate to severe influenza | |
EP1437134A1 (en) | Anti-influenza drugs | |
US20150297512A1 (en) | Local administration-type pharmaceutical for improving dysphagia | |
RU2740657C1 (en) | Antiviral composition | |
US20210299077A1 (en) | Liposomal reduced glutathione (lrg) in combination with ivermectin for the treatment of covid-19 | |
RU2789612C1 (en) | Antiviral pharmaceutical composition containing favipiravir and amino acid hydrate and/or its pharmaceutically acceptable salt | |
RU2783282C1 (en) | Antiviral pharmaceutical composition containing favipiravir and an amino acid, medicinal product containing said composition, and application thereof for treating and/or preventing viral infections | |
RU2814927C1 (en) | Antiviral pharmaceutical composition containing favipiravir and amino acid, drug containing it, as well as their use for treating and/or preventing viral infections | |
US20230201203A1 (en) | Methods of treatment using antifolates and pharmaceutical formulations comprising antifolates | |
US20230330180A1 (en) | Antiviral compositions and methods | |
US20230075092A1 (en) | Combination of diltiazem and viral polymerase inhibitors | |
US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
WO2023192779A2 (en) | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections | |
WO2023085979A1 (en) | Novel derivatives of favipiravir | |
US20230310544A1 (en) | ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG | |
WO2023121629A1 (en) | Combination of camostat mesilat and umifenovir hydrochloride with proton pump inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20931478 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020931478 Country of ref document: EP Effective date: 20221114 |